US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP2270147B2
(en)
|
1999-04-09 |
2020-07-22 |
Kyowa Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US6693176B1
(en)
*
|
1999-07-23 |
2004-02-17 |
University Of Massachusetts |
Antitumor antibodies, proteins, and uses thereof
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US7863020B2
(en)
*
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
EP2322644A1
(en)
|
2000-06-28 |
2011-05-18 |
GlycoFi, Inc. |
Methods for producing modified glycoproteins
|
US7598055B2
(en)
*
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
US8697394B2
(en)
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
US7625756B2
(en)
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
ES2620359T3
(es)
*
|
2000-10-06 |
2017-06-28 |
Kyowa Hakko Kirin Co., Ltd. |
Células que producen unas composiciones de anticuerpo
|
US6946292B2
(en)
*
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP1355666B1
(en)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (RGM) and its modulators
|
CN1541059A
(zh)
*
|
2001-03-06 |
2004-10-27 |
�Ϻ���ͨ��ѧ |
具有动物型糖链加成功能的植物细胞
|
HUP0600342A3
(en)
*
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
AU2002351374A1
(en)
*
|
2001-12-11 |
2003-06-23 |
Corixa Corporation |
Antibodies to treat cancer
|
US20040093621A1
(en)
*
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
EP1467615B2
(en)
|
2001-12-27 |
2017-03-22 |
GlycoFi, Inc. |
Methods to engineer mammalian-type carbohydrate structures
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US6964784B2
(en)
*
|
2002-03-07 |
2005-11-15 |
Optigenex, Inc. |
Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
WO2003085119A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
|
WO2004022597A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化n端ペプチドに対する抗体
|
EP1500400A4
(en)
*
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
WO2003084570A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
|
BR0309145A
(pt)
*
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
CA2481837A1
(en)
*
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
FR2844455B1
(fr)
*
|
2002-09-13 |
2007-12-14 |
Lab Francais Du Fractionnement |
Traitement des pathologies echappant a la reponse immune par des anticorps optimises
|
EP2364996B1
(en)
|
2002-09-27 |
2016-11-09 |
Xencor Inc. |
Optimized FC variants and methods for their generation
|
US20040115204A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Fanger Gary R. |
Antibodies to treat cancer
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
EP1616880A4
(en)
|
2003-03-13 |
2006-07-26 |
Chugai Pharmaceutical Co Ltd |
LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR
|
AU2004226167A1
(en)
*
|
2003-04-03 |
2004-10-14 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antibodies with enhanced ability to immunomodulate cell functions
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
EP2228445A1
(en)
*
|
2003-06-18 |
2010-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose Transporter
|
AU2004256354B2
(en)
|
2003-07-15 |
2011-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM production by transformed cells and methods for quantifying said IgM production
|
FR2858235B1
(fr)
*
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
WO2005014651A1
(ja)
|
2003-08-11 |
2005-02-17 |
Chugai Seiyaku Kabushiki Kaisha |
糖鎖改変抗hm1.24抗体
|
JP4643450B2
(ja)
|
2003-08-08 |
2011-03-02 |
株式会社ペルセウスプロテオミクス |
癌高発現遺伝子
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
AU2004279739A1
(en)
*
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Composition of antibody capable of specifically binding CCR4
|
US20050287138A1
(en)
*
|
2003-10-08 |
2005-12-29 |
Kyowa Hakko Kogyo Co., Ltd. |
CCR4-specific antibody composition
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
AU2004279740A1
(en)
*
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition specifically binding to IL-5 receptor
|
US20050226867A1
(en)
*
|
2003-10-08 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
IL-5R-specific antibody composition
|
WO2005035741A1
(ja)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
ゲノムが改変された細胞
|
US20070128691A1
(en)
*
|
2003-10-09 |
2007-06-07 |
Ryosuke Nakano |
Genomically modified cell neutralized to serum-free system
|
US20060021071A1
(en)
*
|
2003-10-09 |
2006-01-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell in which genome is modified
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
JP4762717B2
(ja)
|
2003-10-09 |
2011-08-31 |
中外製薬株式会社 |
IgM高濃度安定化溶液
|
JPWO2005035778A1
(ja)
*
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
TR201809892T4
(tr)
|
2003-11-05 |
2018-07-23 |
Roche Glycart Ag |
Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
|
EP1697741A4
(en)
|
2003-12-04 |
2008-02-13 |
Xencor Inc |
PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
|
WO2005053742A1
(ja)
*
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
EP1711207B1
(en)
|
2003-12-10 |
2012-11-28 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
NZ547499A
(en)
|
2003-12-10 |
2009-04-30 |
Medarex Inc |
IP-10 antibodies and their uses
|
AU2004299053B2
(en)
*
|
2003-12-15 |
2011-01-06 |
Alexion Pharmaceuticals, Inc. |
Novel anti-DC-SIGN antibodies
|
EP1699822B1
(en)
|
2003-12-30 |
2008-04-23 |
MERCK PATENT GmbH |
Il-7 fusion proteins with antibody portions, their preparation and their use
|
JP2005224240A
(ja)
*
|
2004-01-13 |
2005-08-25 |
Kyowa Hakko Kogyo Co Ltd |
ノックアウト非ヒト動物から樹立された不死化細胞株
|
PT1706428E
(pt)
|
2004-01-22 |
2009-12-29 |
Merck Patent Gmbh |
Anticorpos anticancerígenos com fixação de complemento reduzida
|
AU2005224672B2
(en)
*
|
2004-03-17 |
2011-06-02 |
Glycofi, Inc. |
Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
MXPA06014067A
(es)
*
|
2004-06-04 |
2007-02-15 |
Genentech Inc |
Metodo para tratar lupus.
|
MXPA06014069A
(es)
*
|
2004-06-04 |
2007-04-25 |
Genentech Inc |
Metodo para tratar esclerosis multiple.
|
SI1781705T1
(sl)
|
2004-06-21 |
2015-01-30 |
Medarex, L.L.C. |
Interferon alfa receptor i protitelesa in njihova uporaba
|
RU2427588C2
(ru)
|
2004-07-09 |
2011-08-27 |
Чугаи Сейяку Кабусики Кайся |
Антитело против глипикана 3
|
WO2006005367A1
(en)
|
2004-07-14 |
2006-01-19 |
Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag |
N-glycosylated antibody
|
BRPI0510674A
(pt)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
variantes fc otimizadas
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
KR101300546B1
(ko)
|
2004-08-24 |
2013-09-02 |
추가이 세이야쿠 가부시키가이샤 |
항 글리피칸 3 항체를 이용한 어쥬번트 요법
|
CA2580271A1
(en)
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
TWI468514B
(zh)
|
2004-10-26 |
2015-01-11 |
Chugai Pharmaceutical Co Ltd |
Sugar chain modified phosphatidylinositol glyphosyl 3 antibody
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
WO2006067847A1
(ja)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
ES2755976T3
(es)
|
2005-02-07 |
2020-04-24 |
Roche Glycart Ag |
Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
|
KR101289537B1
(ko)
|
2005-02-15 |
2013-07-31 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
NZ560414A
(en)
|
2005-02-18 |
2011-04-29 |
Medarex Inc |
Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
|
KR101433381B1
(ko)
|
2005-03-23 |
2014-10-02 |
젠맵 에이/에스 |
다발성 골수종의 치료를 위한 cd38에 대한 항체
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
JP2008535494A
(ja)
|
2005-04-07 |
2008-09-04 |
サグレシュ ディスカバリー, インコーポレイテッド |
癌関連遺伝子(prlr)
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
AU2006244445B2
(en)
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
RU2406760C3
(ru)
|
2005-05-09 |
2017-11-28 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
BRPI0613259A2
(pt)
|
2005-05-20 |
2010-12-28 |
Genentech Inc |
método de tratamento de amostra biológica e kit de diagnóstico
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
TW200745160A
(en)
|
2005-06-30 |
2007-12-16 |
Abbott Lab |
IL-12/P40 binding proteins
|
CA3018525C
(en)
|
2005-07-01 |
2023-08-01 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
ES2579602T3
(es)
|
2005-08-10 |
2016-08-12 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2618482C
(en)
|
2005-08-19 |
2014-10-07 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
JP5373396B2
(ja)
|
2005-08-26 |
2013-12-18 |
ロシュ グリクアート アクチェンゲゼルシャフト |
改変された細胞シグナル活性有する改変抗原結合分子
|
US20090214528A1
(en)
*
|
2005-08-31 |
2009-08-27 |
Haimanti Dorai |
Host cell lines for production of antibody constant region with enhanced effector function
|
CA2620515A1
(en)
*
|
2005-09-02 |
2007-03-08 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
|
JP2009507482A
(ja)
*
|
2005-09-09 |
2009-02-26 |
グライコフィ, インコーポレイテッド |
主にman7glcnac2、man8glcnac2グリコフォームを含むイムノグロブリン
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
AU2006302254B2
(en)
|
2005-10-06 |
2011-05-26 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
US8952215B2
(en)
|
2005-10-18 |
2015-02-10 |
Nitto Boseki Co., Ltd. |
Antibody-producing transgenic silkworms and methods for producing the same
|
US7700321B2
(en)
|
2005-10-21 |
2010-04-20 |
Genzyme Corporation |
Antibody-based therapeutics with enhanced ADCC activity
|
CA2625664C
(en)
|
2005-10-21 |
2016-01-05 |
Novartis Ag |
Human antibodies against il13 and therapeutic uses
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
US20080286819A1
(en)
*
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
PL2289909T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
ES2547689T3
(es)
|
2005-12-02 |
2015-10-08 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
|
BRPI0620553A2
(pt)
|
2005-12-08 |
2011-11-16 |
Medarex Inc |
anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-fucosil-gm1 e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando fucosil-gm1
|
KR101397290B1
(ko)
|
2005-12-30 |
2014-05-21 |
메르크 파텐트 게엠베하 |
감소한 면역원성을 가지는 항-cd19 항체
|
PL1966238T3
(pl)
|
2005-12-30 |
2012-09-28 |
Merck Patent Gmbh |
Warianty interleukiny-12p40 o polepszonej stabilności
|
ES2349885T3
(es)
*
|
2006-01-04 |
2011-01-12 |
Novartis Ag |
Análisis de la citotoxicidad celular que depende de anticuerpos.
|
ES2526204T3
(es)
|
2006-01-05 |
2015-01-08 |
Genentech, Inc. |
Anticuerpos anti-EphB4 y métodos para usar los mismos
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
WO2007084922A2
(en)
|
2006-01-17 |
2007-07-26 |
Biolex Therapeutics, Inc. |
Compositions and methods for humanization and optimization of n-glycans in plants
|
WO2008029276A2
(en)
|
2006-02-02 |
2008-03-13 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2004221A2
(en)
|
2006-03-23 |
2008-12-24 |
Novartis Pharma AG |
Anti-tumor cell antigen antibody therapeutics
|
US20080014203A1
(en)
*
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
CN103030696B
(zh)
|
2006-05-30 |
2016-09-28 |
健泰科生物技术公司 |
抗体和免疫偶联物及其用途
|
JP2009539384A
(ja)
|
2006-06-06 |
2009-11-19 |
ジェネンテック・インコーポレーテッド |
抗dll4抗体および抗dll4抗体使用の方法
|
AR061245A1
(es)
*
|
2006-06-06 |
2008-08-13 |
Genentech Inc |
Composiciones y metodos para la modulacion del desarrollo vascular
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
JP2009543579A
(ja)
|
2006-07-19 |
2009-12-10 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
抗炎症反応のための標的としてのWSX−1/p28
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
US20100092457A1
(en)
|
2006-08-14 |
2010-04-15 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
|
EP2383297B8
(en)
|
2006-08-14 |
2023-03-22 |
Xencor, Inc. |
Optimized antibodies that target CD19
|
AU2007292890A1
(en)
|
2006-09-05 |
2008-03-13 |
Medarex, Inc. |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
MX2009002414A
(es)
*
|
2006-09-08 |
2009-05-20 |
Medimmune Llc |
Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
|
CA2914170C
(en)
|
2006-09-08 |
2018-10-30 |
Abbvie Bahamas Ltd. |
Interleukin-13 binding proteins
|
PT2073842E
(pt)
|
2006-09-10 |
2015-04-07 |
Glycotope Gmbh |
Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
HUE027165T2
(en)
|
2006-10-02 |
2016-08-29 |
Squibb & Sons Llc |
Human antibodies that bind to CXCR4 and their uses
|
NZ576032A
(en)
|
2006-10-12 |
2012-03-30 |
Genentech Inc |
Antibodies to lymphotoxin-alpha
|
CA2665528C
(en)
|
2006-10-12 |
2018-01-23 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-ereg antibody
|
US20100061933A1
(en)
|
2006-10-20 |
2010-03-11 |
Naoki Kimura |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
CA2667019C
(en)
|
2006-10-27 |
2016-03-29 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
WO2008076560A2
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to btla and methods of use
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
SG177168A1
(en)
|
2006-12-01 |
2012-01-30 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
US20080127996A1
(en)
*
|
2006-12-04 |
2008-06-05 |
Weinhold Dennis G |
Method and apparatus to remediate an acid and/or liquid spill
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
MX2009006277A
(es)
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
WO2008072723A1
(ja)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
US20110236374A1
(en)
|
2007-01-24 |
2011-09-29 |
Kyowa Hakko Kirin Co., Ltd. |
Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
|
WO2008100805A2
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
DK2447719T3
(en)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
RU2479629C2
(ru)
*
|
2007-03-07 |
2013-04-20 |
Гликофи, Инк. |
Продукция гликопротеинов с модифицированным фукозилированием
|
PT3199180T
(pt)
|
2007-03-08 |
2022-04-01 |
Univ Monash |
Anticorpos epha3 para o tratamento de tumores sólidos
|
WO2008137915A2
(en)
|
2007-05-07 |
2008-11-13 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20100291073A1
(en)
|
2007-05-14 |
2010-11-18 |
Medimmune, Llc |
Methods of reducing eosinophil levels
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
CN107226864A
(zh)
|
2007-06-21 |
2017-10-03 |
宏观基因有限公司 |
共价双抗体及其用途
|
WO2009001840A1
(ja)
|
2007-06-25 |
2008-12-31 |
Forerunner Pharma Research Co., Ltd. |
ADCC活性又はCDC活性を有する抗Prominin-1抗体
|
AU2008272330A1
(en)
*
|
2007-07-04 |
2009-01-08 |
Forerunner Pharma Research Co., Ltd. |
Anti-Muc17 antibody
|
JP2010535032A
(ja)
|
2007-07-31 |
2010-11-18 |
メディミューン,エルエルシー |
多重特異性エピトープ結合性タンパク質およびその用途
|
AU2008282152B2
(en)
|
2007-07-31 |
2013-12-19 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human CD20 and method of using thereof
|
US8501907B2
(en)
|
2007-08-10 |
2013-08-06 |
Janssen Biotech, Inc. |
Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
|
HUE042982T2
(hu)
|
2007-09-04 |
2019-07-29 |
Compugen Ltd |
Polipeptidek és polinukleotidok, és alkalmazásuk drogcélpontként drogok és biológiai szerek elõállítására
|
CA2978687C
(en)
|
2007-09-26 |
2020-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
EP2205258B1
(en)
|
2007-09-28 |
2017-05-24 |
Janssen Biotech, Inc. |
Methods and structural conformations of antibody preparations with increased resistance to proteases
|
MX2010003158A
(es)
*
|
2007-09-28 |
2010-04-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma.
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
CN101951954A
(zh)
|
2007-11-02 |
2011-01-19 |
诺瓦提斯公司 |
调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
|
KR101867606B1
(ko)
|
2007-11-07 |
2018-06-18 |
제넨테크, 인크. |
미생물 질환의 치료를 위한 조성물 및 방법
|
CN102112492B
(zh)
|
2007-11-14 |
2015-02-25 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
BRPI0821658B8
(pt)
|
2007-12-14 |
2021-05-25 |
Novo Nordisk As |
anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
BRPI0821604B1
(pt)
|
2007-12-26 |
2021-09-21 |
Xencor, Inc |
Polipeptídeo isolado compreendendo um fc variante de polipeptídeo de fc de igg humano, método para produzir o mesmo e uso de anticorpo
|
WO2009087978A1
(ja)
|
2008-01-11 |
2009-07-16 |
The University Of Tokyo |
抗cldn6抗体
|
JP2011509675A
(ja)
|
2008-01-18 |
2011-03-31 |
メディミューン,エルエルシー |
部位特異的コンジュゲーションのためのシステイン操作抗体
|
KR20100115360A
(ko)
|
2008-02-05 |
2010-10-27 |
브리스톨-마이어스 스큅 컴퍼니 |
알파 5-베타 1 항체 및 이의 용도
|
KR101666229B1
(ko)
|
2008-02-08 |
2016-10-14 |
메디뮨 엘엘씨 |
Fc 리간드 친화성이 감소된 항-IFNAR1 항체
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
PT2247304T
(pt)
|
2008-04-02 |
2016-08-29 |
Macrogenics Inc |
Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
|
ES2654937T3
(es)
|
2008-04-02 |
2018-02-15 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
NZ588507A
(en)
|
2008-04-11 |
2012-11-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
ES2828627T3
(es)
|
2008-04-25 |
2021-05-27 |
Kyowa Kirin Co Ltd |
Anticuerpo multivalente estable
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
AU2009242038B2
(en)
|
2008-05-02 |
2013-05-30 |
Novartis Ag |
Improved fibronectin-based binding molecules and uses thereof
|
EP2116556B1
(en)
|
2008-05-09 |
2016-03-23 |
AbbVie Deutschland GmbH & Co KG |
Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
SG191639A1
(en)
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
RU2010153578A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
ES2675730T3
(es)
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
WO2010001908A1
(ja)
|
2008-06-30 |
2010-01-07 |
協和発酵キリン株式会社 |
抗cd27抗体
|
KR101054362B1
(ko)
*
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
SG192489A1
(en)
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
DK2325648T3
(da)
|
2008-08-05 |
2014-07-28 |
Toray Industries |
Fremgangsmåde til detektering af cancer
|
MY159396A
(en)
|
2008-08-05 |
2016-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010018846A1
(ja)
*
|
2008-08-13 |
2010-02-18 |
協和発酵キリン株式会社 |
ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
KR101783272B1
(ko)
|
2008-09-17 |
2017-09-29 |
젠코어 인코포레이티드 |
IgE-매개된 장애를 치료하기 위한 신규 조성물 및 방법
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
US8084222B2
(en)
|
2008-09-26 |
2011-12-27 |
Eureka Therapeutics, Inc. |
Methods for generating host cells
|
RU2536937C2
(ru)
|
2008-10-14 |
2014-12-27 |
Дженентек, Инк. |
Варианты иммуноглобулина и их применения
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
GB2466025A
(en)
|
2008-12-08 |
2010-06-09 |
Univ Francois Rabelais De Tour |
C3/ITGAM polymorphisms and cancer prognosis
|
EP2865689A1
(en)
|
2008-12-08 |
2015-04-29 |
Compugen Ltd. |
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
ES2732191T3
(es)
|
2008-12-19 |
2019-11-21 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
EP2388320B1
(en)
|
2008-12-22 |
2017-02-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-hs6st2 antibodies and uses thereof
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
KR101812811B1
(ko)
|
2008-12-23 |
2017-12-27 |
제넨테크, 인크. |
단백질 a에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체
|
EP2385114A4
(en)
|
2008-12-25 |
2012-08-08 |
Univ Tokyo |
CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
|
KR20110099762A
(ko)
|
2008-12-26 |
2011-09-08 |
고쿠리츠다이가쿠호우진 도쿄다이가쿠 |
항lgr7항체를 사용하는 암의 진단 및 치료
|
PL2374883T3
(pl)
*
|
2008-12-26 |
2017-05-31 |
Kyowa Hakko Kirin Co., Ltd. |
Przeciwciało anty-CD4
|
DK2379598T3
(en)
|
2009-01-19 |
2015-06-15 |
Innate Pharma |
Anti-kir3d antibodies
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
PL2403878T3
(pl)
|
2009-03-05 |
2017-12-29 |
E. R. Squibb & Sons, L.L.C. |
W pełni ludzkie przeciwciała specyficzne dla CADM1
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
EP2403879A1
(en)
|
2009-03-06 |
2012-01-11 |
Kalobios Pharmaceuticals, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
KR101822663B1
(ko)
|
2009-03-25 |
2018-01-29 |
제넨테크, 인크. |
항-fgfr3 항체 및 그의 사용 방법
|
SG174515A1
(en)
|
2009-03-25 |
2011-10-28 |
Genentech Inc |
NOVEL ANTI-a5ß1 ANTIBODIES AND USES THEREOF
|
AR075982A1
(es)
|
2009-03-31 |
2011-05-11 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
CA2757931C
(en)
|
2009-04-07 |
2019-03-26 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
CN102361884A
(zh)
|
2009-04-07 |
2012-02-22 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-2/抗-c-Met抗体
|
EP2417159A1
(en)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-3/anti-c-met antibodies
|
WO2010117011A1
(ja)
|
2009-04-09 |
2010-10-14 |
第一三共株式会社 |
抗Siglec-15抗体
|
EP2417984B1
(en)
|
2009-04-10 |
2016-03-30 |
Kyowa Hakko Kirin Co., Ltd. |
Method for treatment of blood tumor using anti-tim-3 antibody
|
WO2010119691A1
(ja)
|
2009-04-16 |
2010-10-21 |
国立大学法人東京大学 |
抗tmprss11e抗体を用いた癌の診断と治療
|
AU2010239351C1
(en)
|
2009-04-20 |
2015-02-05 |
Oxford Biotherapeutics Ltd. |
Antibodies specific to Cadherin-17
|
HUE028537T2
(en)
|
2009-04-20 |
2016-12-28 |
Kyowa Hakko Kirin Co Ltd |
Built-in amino acid mutation IgG2 antibody
|
US8715657B2
(en)
|
2009-04-27 |
2014-05-06 |
Novartis Ag |
Therapeutic antibodies binding IL12Rβ1
|
PT2426148E
(pt)
|
2009-04-27 |
2015-10-26 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
|
AR076402A1
(es)
|
2009-04-27 |
2011-06-08 |
Novartis Ag |
Composiciones y metodos para aumentar el crecimiento muscular
|
EP2426149A4
(en)
|
2009-05-01 |
2013-01-23 |
Univ Tokyo |
ANTI-CADHERIN ANTIBODY
|
KR20120024763A
(ko)
|
2009-05-15 |
2012-03-14 |
추가이 세이야쿠 가부시키가이샤 |
항axl 항체
|
WO2010138184A2
(en)
|
2009-05-27 |
2010-12-02 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
JP5719354B2
(ja)
|
2009-05-27 |
2015-05-20 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
三重又は四重特異性抗体
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
AU2010256753B2
(en)
|
2009-06-02 |
2013-11-28 |
Regeneron Pharmaceuticals, Inc. |
Fucosylation-deficient cells
|
KR101812348B1
(ko)
|
2009-06-11 |
2017-12-26 |
다이가쿠쿄도리요우키칸호우진 죠우호우시스테무 겡큐키코우 |
단백질의 생산 방법
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
WO2010146550A1
(en)
|
2009-06-18 |
2010-12-23 |
Pfizer Inc. |
Anti notch-1 antibodies
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
ES2513292T3
(es)
|
2009-07-31 |
2014-10-24 |
Genentech, Inc. |
Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
|
US8563694B2
(en)
|
2009-07-31 |
2013-10-22 |
Medarex, Inc. |
Fully human antibodies to BTLA
|
ES2661601T3
(es)
|
2009-08-07 |
2018-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo humanizado antioligómero de amiloide-beta
|
EP2463369A4
(en)
|
2009-08-07 |
2013-09-18 |
Kyowa Hakko Kirin Co Ltd |
HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
WO2011018225A1
(en)
|
2009-08-14 |
2011-02-17 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
|
AU2010285974A1
(en)
|
2009-08-17 |
2012-03-22 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
BR112012003983A2
(pt)
|
2009-08-31 |
2021-09-14 |
Roche Glycart Ag |
Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção
|
RU2012112550A
(ru)
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
KR101545914B1
(ko)
|
2009-09-22 |
2015-08-20 |
프로바이오겐 아게 |
특수화된 글리칸 구조를 함유하는 분자의 생산 방법
|
MX2012004029A
(es)
|
2009-10-07 |
2012-05-08 |
Macrogenics Inc |
Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
CA2777068C
(en)
|
2009-10-14 |
2020-05-26 |
Kalobios Pharmaceuticals, Inc. |
Antibodies to epha3
|
WO2011047262A2
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
NZ599337A
(en)
|
2009-10-22 |
2013-05-31 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
KR102223417B1
(ko)
|
2009-10-26 |
2021-03-05 |
에프. 호프만-라 로슈 아게 |
글리코실화된 면역글로불린의 제조 방법
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JP2013509415A
(ja)
|
2009-10-29 |
2013-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
抗体グリコシル化変異型
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
WO2011054007A1
(en)
|
2009-11-02 |
2011-05-05 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
JP6007420B2
(ja)
|
2009-11-04 |
2016-10-12 |
ファブラス エルエルシー |
親和性成熟に基づく抗体最適化方法
|
NZ599761A
(en)
|
2009-11-04 |
2014-04-30 |
Merck Sharp & Dohme |
Engineered anti-tslp antibody
|
NZ598901A
(en)
|
2009-11-05 |
2014-08-29 |
Genentech Inc |
Methods and composition for secretion of heterologous polypeptides
|
PL3279215T3
(pl)
|
2009-11-24 |
2020-06-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
EP2507265B1
(en)
|
2009-12-01 |
2016-05-11 |
Compugen Ltd. |
Antibody specific for heparanase splice variant T5 and its use.
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
JP5818805B2
(ja)
|
2009-12-11 |
2015-11-18 |
ジェネンテック, インコーポレイテッド |
抗vegf−c抗体及びその使用方法
|
JP5680671B2
(ja)
|
2009-12-22 |
2015-03-04 |
ロシュ グリクアート アーゲー |
抗her3抗体及びその使用
|
TW201130511A
(en)
|
2009-12-22 |
2011-09-16 |
Novartis Ag |
Soluble proteins for use as therapeutics
|
PL2516465T3
(pl)
|
2009-12-23 |
2016-11-30 |
|
Przeciwciała anty-bv8 i ich zastosowania
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
TR201806936T4
(tr)
|
2010-01-29 |
2018-06-21 |
Chugai Pharmaceutical Co Ltd |
Anti-dll3 antikoru.
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
EP2535358B1
(en)
|
2010-02-10 |
2017-12-20 |
Fujifilm RI Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
US9173961B2
(en)
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
JP6050124B2
(ja)
|
2010-02-19 |
2016-12-21 |
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ |
Wntシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法
|
WO2011105573A1
(ja)
|
2010-02-26 |
2011-09-01 |
株式会社未来創薬研究所 |
抗icam3抗体およびその用途
|
JP5820800B2
(ja)
|
2010-03-02 |
2015-11-24 |
協和発酵キリン株式会社 |
改変抗体組成物
|
NZ602161A
(en)
|
2010-03-04 |
2014-12-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
TW201138823A
(en)
|
2010-03-24 |
2011-11-16 |
Genentech Inc |
Anti-LRP6 antibodies
|
US9631018B2
(en)
|
2010-03-26 |
2017-04-25 |
The Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CA2794708C
(en)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
EP2558494B1
(en)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
WO2011134899A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
ES2635594T3
(es)
|
2010-05-14 |
2017-10-04 |
Abbvie Inc. |
Proteínas de unión a IL-1
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
EP2576622A4
(en)
|
2010-06-01 |
2013-11-27 |
Univ Monash |
ANTIBODIES AGAINST RECEPTOR TYROSINE KINASE C-MET
|
MX336109B
(es)
|
2010-06-03 |
2016-01-08 |
Genentech Inc |
Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
|
ES2682078T3
(es)
*
|
2010-06-11 |
2018-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-TIM-3
|
EP2582729A4
(en)
|
2010-06-18 |
2014-05-28 |
Hoffmann La Roche |
ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
|
AU2011268110B2
(en)
|
2010-06-19 |
2016-05-19 |
Memorial Sloan-Kettering Cancer Center |
Anti-GD2 antibodies
|
WO2011163401A2
(en)
|
2010-06-22 |
2011-12-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
EP2588862A2
(en)
|
2010-07-01 |
2013-05-08 |
Glaxo Group Limited |
Improved method for selecting high producing cell lines
|
EP2592161B1
(en)
|
2010-07-08 |
2016-02-03 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
KR20130120439A
(ko)
|
2010-07-09 |
2013-11-04 |
제넨테크, 인크. |
항-뉴로필린 항체 및 사용 방법
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
CN103052649B
(zh)
|
2010-07-29 |
2015-12-16 |
Xencor公司 |
具有修改的等电点的抗体
|
WO2012013823A2
(en)
|
2010-07-30 |
2012-02-02 |
Glycode |
A yeast artificial chromosome carrying the mammalian glycosylation pathway
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JP2013541501A
(ja)
|
2010-08-03 |
2013-11-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
慢性リンパ性白血病(cll)のバイオマーカー
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
|
WO2012020006A2
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
EP2603529A1
(en)
|
2010-08-13 |
2013-06-19 |
Roche Glycart AG |
Anti-tenascin-c a2 antibodies and methods of use
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
UA114883C2
(uk)
|
2010-08-20 |
2017-08-28 |
Новартіс Аг |
Антитіло до рецептора епідермального фактора росту-3 (her3)
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
TW201215405A
(en)
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
RU2013113638A
(ru)
|
2010-08-27 |
2014-10-10 |
Стем Сентркс, Инк. |
МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
WO2012035518A1
(en)
|
2010-09-17 |
2012-03-22 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
ES2719624T3
(es)
|
2010-09-23 |
2019-07-11 |
Prec Biologics Inc |
Peptidomiméticos de cáncer de colon y de páncreas
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
KR101814852B1
(ko)
|
2010-10-29 |
2018-01-04 |
다이이찌 산쿄 가부시키가이샤 |
신규 항 dr5 항체
|
DK2635607T3
(da)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
JP6163429B2
(ja)
|
2010-11-10 |
2017-07-12 |
ジェネンテック, インコーポレイテッド |
神経疾患免疫治療のための方法及び組成物
|
US9334331B2
(en)
|
2010-11-17 |
2016-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies
|
NZ610460A
(en)
*
|
2010-11-19 |
2015-01-30 |
Janssen Biotech Inc |
Immunoglobulin cleavage fragments vaccine compositions
|
DK2643018T3
(da)
|
2010-11-23 |
2021-01-18 |
Vitaeris Inc |
Anti-il-6-antistoffer til behandling af oral mucositis
|
HUE039412T2
(hu)
|
2010-11-23 |
2018-12-28 |
Glaxo Group Ltd |
Antigén megkötõ proteinek oncostatin M (OSM) megkötésére
|
SG190362A1
(en)
|
2010-11-24 |
2013-06-28 |
Glaxo Group Ltd |
Multispecific antigen binding proteins targeting hgf
|
CN107973851A
(zh)
|
2010-11-30 |
2018-05-01 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
KR101026999B1
(ko)
|
2010-12-08 |
2011-04-11 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
RU2592672C9
(ru)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Новые модуляторы и способы их применения
|
WO2012076670A2
(en)
|
2010-12-10 |
2012-06-14 |
Novartis Ag |
Antibody formulation
|
SG191124A1
(en)
|
2010-12-15 |
2013-07-31 |
Kek High Energy Accelerator |
Protein production method
|
RU2622083C2
(ru)
|
2010-12-15 |
2017-06-09 |
ВАЙЕТ ЭлЭлСи |
Антитела против notch1
|
EP2653541B1
(en)
|
2010-12-15 |
2017-11-08 |
Kyowa Hakko Kirin Co., Ltd. |
Method for producing proteins
|
EP3447491A3
(en)
|
2010-12-16 |
2019-06-05 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to th2 inhibition
|
RU2013131444A
(ru)
|
2010-12-16 |
2015-01-27 |
Рош Гликарт Аг |
Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
DK2654780T3
(en)
|
2010-12-23 |
2017-04-10 |
Janssen Biotech Inc |
ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
FR2971250A1
(fr)
|
2011-02-07 |
2012-08-10 |
Univ Nantes |
Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
|
KR20130118941A
(ko)
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012116927A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
CA2825081A1
(en)
|
2011-02-28 |
2012-09-07 |
Birgit Bossenmaier |
Antigen binding proteins
|
HUE036229T2
(hu)
|
2011-03-02 |
2018-06-28 |
Roche Glycart Ag |
CEA antitestek
|
WO2012127045A1
(en)
|
2011-03-23 |
2012-09-27 |
Glycode |
A yeast recombinant cell capable of producing gdp-fucose
|
KR20140021589A
(ko)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
항-fgfr4 항체 및 사용 방법
|
SG10201603034TA
(en)
|
2011-04-15 |
2016-05-30 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
JP6104794B2
(ja)
|
2011-04-18 |
2017-03-29 |
国立大学法人 東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
ES2625818T3
(es)
|
2011-04-19 |
2017-07-20 |
Merrimack Pharmaceuticals, Inc. |
Anticuerpos biespecíficos anti-IGF-1R y anti-ErbB3
|
JP5917498B2
(ja)
|
2011-04-25 |
2016-05-18 |
第一三共株式会社 |
抗b7−h3抗体
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
RU2638806C2
(ru)
|
2011-05-12 |
2017-12-15 |
Дженентек, Инк. |
Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов
|
PT2707391T
(pt)
|
2011-05-13 |
2018-02-06 |
Inserm Institut National De La Santa© Et De La Rech Ma©Dicale |
Anticorpos contra her3
|
HUE033584T2
(hu)
|
2011-05-16 |
2017-12-28 |
Hoffmann La Roche |
FGFR1 agonisták és alkalmazási eljárások
|
JP6145088B2
(ja)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
SG195082A1
(en)
|
2011-05-25 |
2013-12-30 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory disorders
|
CN106279418A
(zh)
|
2011-05-27 |
2017-01-04 |
葛兰素集团有限公司 |
Bcma(cd269/tnfrsf17)结合蛋白
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012174001A1
(en)
|
2011-06-13 |
2012-12-20 |
Abgenomics Cooperatief U.A. |
Anti-psgl-1 antibodies and uses thereof
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
CN103596984B
(zh)
|
2011-06-15 |
2016-04-13 |
霍夫曼-拉罗奇有限公司 |
抗-人epo受体的抗体及使用方法
|
AU2012269929A1
(en)
|
2011-06-16 |
2013-12-12 |
Novartis Ag |
Soluble proteins for use as therapeutics
|
US20140120555A1
(en)
*
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
AU2012274461A1
(en)
|
2011-06-20 |
2014-01-16 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-erbB3 antibody
|
RU2014101707A
(ru)
|
2011-06-22 |
2015-07-27 |
Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) |
АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
|
FR2976811A1
(fr)
|
2011-06-22 |
2012-12-28 |
Lfb Biotechnologies |
Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
|
EA201400046A1
(ru)
|
2011-06-22 |
2014-07-30 |
Ф. Хоффманн-Ля Рош Аг |
Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
|
AU2012273954A1
(en)
|
2011-06-22 |
2014-01-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
GEP201706667B
(en)
|
2011-06-28 |
2017-05-25 |
Berlin - Chemie Ag |
Antibodies to adp-ribosyl cyclase 2
|
LT2726094T
(lt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Gydymo ir diagnozavimo objektas
|
EP2726098A1
(en)
|
2011-06-30 |
2014-05-07 |
F.Hoffmann-La Roche Ag |
Anti-c-met antibody formulations
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
DK2726099T3
(en)
|
2011-07-01 |
2018-11-05 |
Novartis Ag |
Method of treating metabolic disorders
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013009521A2
(en)
|
2011-07-13 |
2013-01-17 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
JP2014526886A
(ja)
|
2011-07-15 |
2014-10-09 |
モルフォシス・アー・ゲー |
マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
|
AU2012288846B2
(en)
|
2011-07-27 |
2016-05-19 |
Glaxo Group Limited |
Anti-VEGF single variable domains fused to fc domains
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
CA2842481A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
CN103890007A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
神经调节蛋白抗体及其用途
|
BR112014003999A2
(pt)
|
2011-08-23 |
2017-06-13 |
Roche Glycart Ag |
anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
|
WO2013026831A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
KR20140068062A
(ko)
|
2011-09-15 |
2014-06-05 |
제넨테크, 인크. |
분화의 촉진 방법
|
EP2758055A1
(en)
|
2011-09-19 |
2014-07-30 |
F.Hoffmann-La Roche Ag |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
KR101684750B1
(ko)
|
2011-09-23 |
2016-12-08 |
로슈 글리카트 아게 |
이중특이적 항-egfr/항-igf-1r 항체
|
BR112014007487A2
(pt)
|
2011-09-30 |
2017-04-04 |
Dana Farber Cancer Inst Inc |
peptídeos terapêuticos
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
RU2722829C9
(ru)
|
2011-09-30 |
2020-09-22 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
|
CA2849011A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
CN104080471B
(zh)
|
2011-10-14 |
2018-08-10 |
诺华股份有限公司 |
用于Wnt途径相关疾病的抗体和方法
|
CA2850032C
(en)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
EA201490879A1
(ru)
|
2011-10-28 |
2014-08-29 |
Дженентек, Инк. |
Терапевтические комбинации и способы лечения меланомы
|
JP6291254B2
(ja)
|
2011-10-28 |
2018-03-14 |
中外製薬株式会社 |
癌幹細胞特異的分子
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
HRP20211773T1
(hr)
|
2011-11-04 |
2022-03-04 |
Zymeworks Inc. |
Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
|
EP2776061B1
(en)
|
2011-11-07 |
2019-08-14 |
MedImmune, LLC |
Multispecific and multivalent binding proteins and uses thereof
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
BR112014013412A8
(pt)
|
2011-12-05 |
2021-06-08 |
Novartis Ag |
anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
WO2013087789A1
(en)
|
2011-12-13 |
2013-06-20 |
Glykos Finland Ltd. |
Antibody isoform arrays and methods thereof
|
SI2794905T1
(sl)
|
2011-12-20 |
2020-08-31 |
Medimmune, Llc |
Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
|
ES2728278T3
(es)
|
2011-12-21 |
2019-10-23 |
Novartis Ag |
Composiciones que comprenden anticuerpos dirigidos al factor P y C5
|
US9963511B2
(en)
|
2011-12-22 |
2018-05-08 |
Hoffmann-La Roche Inc. |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
RU2639519C2
(ru)
|
2011-12-22 |
2017-12-21 |
Ф.Хоффманн-Ля Рош Аг |
Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
|
WO2013092720A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
MX2014008101A
(es)
|
2011-12-30 |
2014-09-25 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
EP2802603A4
(en)
|
2012-01-09 |
2015-11-04 |
Scripps Research Inst |
REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
BR112014017518A2
(pt)
|
2012-01-18 |
2018-09-04 |
Genentech Inc |
anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
|
HUE039611T2
(hu)
|
2012-01-27 |
2019-01-28 |
Abbvie Deutschland |
Készítmények és eljárások axondegenerációval járó betegségek diagnózisára és kezelésére
|
AU2013215332A1
(en)
|
2012-01-31 |
2014-09-04 |
Genentech, Inc. |
Anti-Ig-E M1' antibodies and methods using same
|
IN2014KN00848A
(US20050276830A1-20051215-C00018.png)
|
2012-02-01 |
2015-10-02 |
Compugen Ltd |
|
AU2013218017B2
(en)
|
2012-02-07 |
2017-12-07 |
Innate Pharma |
MICA binding agents
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
AU2013216753B2
(en)
|
2012-02-11 |
2017-09-21 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
CN104125852B9
(zh)
|
2012-02-15 |
2017-05-17 |
弗·哈夫曼-拉罗切有限公司 |
基于Fc‑受体的亲和色谱
|
AU2013234046B2
(en)
|
2012-03-16 |
2017-09-07 |
University Health Network |
Methods and compositions for modulating Toso activity
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
JPWO2013147212A1
(ja)
|
2012-03-30 |
2015-12-14 |
第一三共株式会社 |
新規抗Siglec−15抗体
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
CA2868959A1
(en)
|
2012-03-30 |
2013-10-03 |
Daiichi Sankyo Company, Limited |
Cdr-modified anti-siglec-15 antibody
|
KR102115143B1
(ko)
|
2012-04-09 |
2020-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항 fgfr2 항체
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
MX356749B
(es)
|
2012-04-27 |
2018-06-12 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-homologo 4 de roundabout (robo4).
|
WO2013165940A1
(en)
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
JP6351572B2
(ja)
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Fcドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EP2852610B1
(en)
|
2012-05-23 |
2018-07-11 |
Glykos Finland Oy |
Production of fucosylated glycoproteins
|
MX2014014086A
(es)
|
2012-05-23 |
2015-01-26 |
Genentech Inc |
Metodo de seleccion para agentes terapeuticos.
|
CA2869529A1
(en)
|
2012-05-24 |
2013-11-28 |
Raffaella CASTOLDI |
Multispecific antibodies
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
MX2014014894A
(es)
|
2012-06-04 |
2015-02-20 |
Irm Llc |
Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
JP6285923B2
(ja)
|
2012-06-22 |
2018-02-28 |
トラスティーズ・オブ・ダートマス・カレッジ |
新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用
|
CA2871880A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
MX2014014804A
(es)
|
2012-06-27 |
2015-02-12 |
Hoffmann La Roche |
Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
EP3138580B1
(en)
|
2012-07-04 |
2021-03-03 |
F. Hoffmann-La Roche AG |
Covalently linked antigen-antibody conjugates
|
BR112014030844A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
US9803191B2
(en)
|
2012-07-05 |
2017-10-31 |
Genentech, Inc. |
Expression and secretion system
|
WO2014007303A1
(ja)
|
2012-07-06 |
2014-01-09 |
学校法人 聖マリアンナ医科大学 |
Htlv-1関連脊髄症患者の治療方法および治療剤
|
EA201590171A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
|
CN104411337A
(zh)
|
2012-07-09 |
2015-03-11 |
基因泰克公司 |
包含抗cd79b抗体的免疫偶联物
|
US20140030279A1
(en)
|
2012-07-09 |
2014-01-30 |
Spirogen Sarl |
Anti-cd22 antibodies and immunoconjugates
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
RS57704B1
(sr)
|
2012-07-13 |
2018-12-31 |
Roche Glycart Ag |
Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka
|
CN104394887A
(zh)
|
2012-07-18 |
2015-03-04 |
葛莱高托普有限公司 |
采用具有低岩藻糖化的抗her2抗体的新治疗性疗法
|
CA2880007C
(en)
|
2012-07-25 |
2021-12-28 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
ES2848732T3
(es)
|
2012-08-07 |
2021-08-11 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
EP2888279A1
(en)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
WO2014051022A1
(ja)
|
2012-09-27 |
2014-04-03 |
中外製薬株式会社 |
Fgfr3融合遺伝子およびそれを標的とする医薬
|
WO2014054804A1
(ja)
|
2012-10-05 |
2014-04-10 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
KR102237639B1
(ko)
|
2012-10-11 |
2021-04-07 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트
|
US9872924B2
(en)
|
2012-10-19 |
2018-01-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
WO2014071074A2
(en)
|
2012-11-01 |
2014-05-08 |
Abbvie Inc. |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
CA2890575C
(en)
|
2012-11-05 |
2021-11-09 |
Jumpei Enami |
Antibody and antibody composition production method
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
EP2917243B1
(en)
|
2012-11-08 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
EP3461501A1
(en)
|
2012-11-13 |
2019-04-03 |
F. Hoffmann-La Roche AG |
Anti-hemagglutinin antibodies and methods of use
|
EP2733153A1
(en)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the preparation of immunoconjugates and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
JP2016500251A
(ja)
|
2012-12-03 |
2016-01-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
免疫調節Fc融合タンパク質の抗癌活性の増強
|
HUE053669T2
(hu)
|
2012-12-05 |
2021-07-28 |
Novartis Ag |
Készítmények és eljárások EPO-t célzó antitestekre
|
CN105025923B
(zh)
|
2012-12-06 |
2018-03-27 |
国立大学法人金泽大学 |
间皮瘤的治疗方法
|
TWI614266B
(zh)
|
2012-12-07 |
2018-02-11 |
Kyowa Hakko Kirin Co Ltd |
抗folr1抗體
|
WO2014096672A1
(fr)
|
2012-12-17 |
2014-06-26 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
AU2013360775B2
(en)
|
2012-12-21 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent MHC class I comprising multi-function proteins
|
EP4119947A1
(en)
|
2012-12-21 |
2023-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
|
WO2014106004A2
(en)
|
2012-12-28 |
2014-07-03 |
Abbvie, Inc. |
High-throughput system and method for identifying antibodies having specific antigen binding activities
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
AU2013370171B2
(en)
|
2012-12-28 |
2018-09-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
EA201500741A1
(ru)
|
2013-01-10 |
2016-01-29 |
Генмаб Б.В. |
ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
SI2943511T1
(sl)
|
2013-01-14 |
2020-01-31 |
Xencor, Inc. |
Novi heterodimerni proteini
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
EP2948177A1
(en)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2953972B1
(en)
|
2013-02-05 |
2020-07-08 |
EngMab Sàrl |
Method for the selection of antibodies against bcma
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
UY35315A
(es)
|
2013-02-08 |
2014-09-30 |
Novartis Ag |
Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
|
PL2953976T3
(pl)
|
2013-02-08 |
2021-11-02 |
Novartis Ag |
Specyficzne miejsca modyfikowania przeciwciał dla wytwarzania immunokoniugatów
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
DK2956482T3
(en)
|
2013-02-14 |
2017-10-16 |
Innate Pharma |
TREATMENT OF PERFECT T cell lymphoma
|
ES2878749T3
(es)
|
2013-02-20 |
2021-11-19 |
Innate Pharma |
Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
|
WO2014130613A2
(en)
|
2013-02-22 |
2014-08-28 |
Amgen Inc. |
Carbohydrate phosphonate derivatives as modulators of glycosylation
|
MX2015010791A
(es)
|
2013-02-22 |
2015-11-26 |
Hoffmann La Roche |
Metodos para tratar el cancer y prevenir la resistencia a farmacos.
|
CA2896259A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック, インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
EP2964676A1
(en)
|
2013-03-06 |
2016-01-13 |
Merrimack Pharmaceuticals, Inc. |
Anti-c-met tandem fc bispecific antibodies
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
EP2975054A4
(en)
|
2013-03-12 |
2016-11-23 |
Zenyaku Kogyo Kk |
ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
Hcvコア脂質結合ドメインモノクローナル抗体
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
WO2014143342A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
MX2015012872A
(es)
|
2013-03-15 |
2016-02-03 |
Ac Immune Sa |
Anticuerpos anti-tau y metodos de uso.
|
CN118547067A
(zh)
|
2013-03-15 |
2024-08-27 |
豪夫迈·罗氏有限公司 |
治疗pd-1和pd-l1相关疾患的生物标志物和方法
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
KR20150128707A
(ko)
|
2013-03-15 |
2015-11-18 |
제넨테크, 인크. |
간암의 진단 및 치료를 위한 조성물 및 방법
|
EA201591559A1
(ru)
|
2013-03-15 |
2016-03-31 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Терапевтические пептиды
|
AU2014235474B2
(en)
|
2013-03-15 |
2017-05-25 |
Novartis Ag |
Antibody drug conjugates
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
KR102211176B1
(ko)
|
2013-03-15 |
2021-02-01 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
EP2968545B1
(en)
|
2013-03-15 |
2019-03-06 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-gd2 antibodies
|
EA035645B1
(ru)
|
2013-03-15 |
2020-07-21 |
Дженентек, Инк. |
ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
KR20150131177A
(ko)
|
2013-03-15 |
2015-11-24 |
제넨테크, 인크. |
항-CRTh2 항체 및 그의 용도
|
PL2970464T3
(pl)
|
2013-03-15 |
2020-10-05 |
Glaxosmithkline Intellectual Property Development Limited |
Wiążące białka anty-lag-3
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
WO2014173886A1
(en)
|
2013-04-22 |
2014-10-30 |
Glycotope Gmbh |
Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
|
WO2014177459A2
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
SG10201800492PA
(en)
|
2013-04-29 |
2018-03-28 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
PE20151925A1
(es)
|
2013-04-29 |
2015-12-26 |
Hoffmann La Roche |
Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
|
US9708406B2
(en)
|
2013-05-20 |
2017-07-18 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
BR112015029838A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
|
RU2687044C2
(ru)
|
2013-05-31 |
2019-05-06 |
Дженентек, Инк. |
Антитела против стеночной тейхоевой кислоты и их конъюгаты
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
JPWO2014208482A1
(ja)
|
2013-06-24 |
2017-02-23 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
PE20210949A1
(es)
|
2013-08-01 |
2021-05-24 |
Five Prime Therapeutics Inc |
Anticuerpos anti-fgfr2iiib afucosilados
|
PL3031826T3
(pl)
*
|
2013-08-09 |
2019-03-29 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
|
CA2918105C
(en)
|
2013-08-12 |
2023-02-28 |
Medimmune, Llc |
Methods for reducing exacerbation rates of asthma using benralizumab
|
EP3520811B1
(en)
|
2013-08-12 |
2020-12-30 |
Astrazeneca AB |
Methods for increasing forced expiratory volume in asthmatics using benralizumab
|
TR201910413T4
(tr)
|
2013-08-12 |
2019-08-21 |
Astrazeneca Ab |
Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
RU2016108652A
(ru)
|
2013-08-14 |
2017-09-14 |
Новартис Аг |
Способы лечения спорадического миозита с тельцами включений
|
US20160251410A1
(en)
|
2013-09-03 |
2016-09-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compositions and methods for expressing recombinant polypeptides
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
MX2016003643A
(es)
|
2013-09-30 |
2016-12-20 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lps o11.
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN118005782A
(zh)
|
2013-10-02 |
2024-05-10 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
KR20160066024A
(ko)
|
2013-10-08 |
2016-06-09 |
다이이찌 산쿄 가부시키가이샤 |
항 fgfr2 항체와 타제의 조합
|
EP3620470B1
(en)
|
2013-10-11 |
2023-07-26 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
KR102357173B1
(ko)
|
2013-10-11 |
2022-01-27 |
옥스포드 바이오테라퓨틱스 리미티드 |
암을 치료하기 위한 ly75에 대한 접합 항체
|
KR20160068855A
(ko)
|
2013-10-11 |
2016-06-15 |
제넨테크, 인크. |
Nsp4 억제제 및 사용 방법
|
MX2016003593A
(es)
|
2013-10-11 |
2016-06-02 |
Hoffmann La Roche |
Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
|
CN113230399A
(zh)
*
|
2013-10-15 |
2021-08-10 |
阿斯利康(瑞典)有限公司 |
用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
MX2016004802A
(es)
|
2013-10-18 |
2016-07-18 |
Genentech Inc |
Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
CN105849280B
(zh)
|
2013-10-23 |
2020-11-06 |
豪夫迈·罗氏有限公司 |
诊断和治疗嗜酸性粒细胞紊乱的方法
|
BR112016010336A2
(pt)
|
2013-11-07 |
2017-10-03 |
Inst Nat Sante Rech Med |
Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2015075011A1
(en)
|
2013-11-21 |
2015-05-28 |
F. Hoffmann-La Roche Ag |
ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
CN105980557B
(zh)
|
2013-12-04 |
2020-04-07 |
中外制药株式会社 |
抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
|
US10106611B2
(en)
|
2013-12-06 |
2018-10-23 |
Dana-Farber Cancer Institute, Inc. |
Antibodies that bind to MHC class I polypeptide-related sequence A
|
ES2758508T3
(es)
|
2013-12-09 |
2020-05-05 |
Allakos Inc |
Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos
|
AR098743A1
(es)
|
2013-12-13 |
2016-06-08 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
EP3083689B1
(en)
|
2013-12-17 |
2020-05-27 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
WO2015095410A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
AU2014364601A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
|
CN117986366A
(zh)
|
2013-12-20 |
2024-05-07 |
英特维特国际股份有限公司 |
拮抗性抗犬pd-1抗体
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
CN116987193A
(zh)
|
2013-12-25 |
2023-11-03 |
第一三共株式会社 |
抗trop2抗体-药物偶联物
|
HUE064292T2
(hu)
|
2013-12-26 |
2024-03-28 |
Mitsubishi Tanabe Pharma Corp |
Humán anti-IL-33 semlegesítõ monoklonális antitest
|
DK3087986T3
(da)
|
2013-12-27 |
2019-12-02 |
Chugai Pharmaceutical Co Ltd |
Mutant fgfr-gatekeepergen og aktivt stof rettet mod samme
|
BR112016012666A2
(pt)
|
2014-01-03 |
2017-09-26 |
Hoffmann La Roche |
conjugado, anticorpos, formulação farmacêutica e usos de conjugado
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP6521464B2
(ja)
|
2014-01-03 |
2019-05-29 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
|
EP3089996B1
(en)
|
2014-01-03 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
FR3016633B1
(fr)
|
2014-01-17 |
2018-04-13 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Immunoglobuline anti-toxine du charbon
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
CN106413756A
(zh)
|
2014-01-24 |
2017-02-15 |
豪夫迈·罗氏有限公司 |
使用抗steap1抗体和免疫缀合物的方法
|
IL278891B2
(en)
|
2014-01-31 |
2024-06-01 |
Daiichi Sankyo Co Ltd |
Anti-HER2 drug-antibody conjugates, preparations containing them and their uses
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
SG11201606316XA
(en)
|
2014-02-08 |
2016-08-30 |
Genentech Inc |
Methods of treating alzheimer's disease
|
SG10201901076WA
(en)
|
2014-02-08 |
2019-03-28 |
Genentech Inc |
Methods of treating alzheimer's disease
|
AU2015217271B2
(en)
|
2014-02-12 |
2018-10-25 |
Genentech, Inc. |
Anti-Jagged1 antibodies and methods of use
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
TWI558399B
(zh)
|
2014-02-26 |
2016-11-21 |
美國禮來大藥廠 |
癌症之組合療法
|
WO2015131155A1
(en)
|
2014-02-28 |
2015-09-03 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
US20150252434A1
(en)
|
2014-03-07 |
2015-09-10 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
KR20160125515A
(ko)
|
2014-03-12 |
2016-10-31 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
EP3925973A1
(en)
|
2014-03-14 |
2021-12-22 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
JP6644717B2
(ja)
|
2014-03-14 |
2020-02-12 |
ジェネンテック, インコーポレイテッド |
異種ポリペプチドを分泌させるための方法及び組成物
|
CA2939204C
(en)
|
2014-03-14 |
2023-06-27 |
Innate Pharma |
Humanized antibodies with increased stability
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
PE20161211A1
(es)
|
2014-03-21 |
2016-11-27 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
CR20160500A
(es)
|
2014-03-31 |
2016-12-14 |
Genentech Inc |
Anticuerpos anti-ox40 y métodos de uso
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
KR101660580B1
(ko)
|
2014-04-02 |
2016-09-28 |
프레스티지 바이오파마 피티이. 엘티디. |
항체의 당 함량 조절을 통한 항체의 제조 방법
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
KR101937549B1
(ko)
|
2014-04-10 |
2019-01-10 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
US10160812B2
(en)
|
2014-04-11 |
2018-12-25 |
Medimmune, Llc |
Bispecific HER2 antibodies
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
EP3141603A4
(en)
|
2014-05-08 |
2017-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
RU2016144405A
(ru)
|
2014-05-23 |
2018-06-26 |
Дженентек, Инк. |
MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
PL3148581T3
(pl)
|
2014-05-30 |
2020-05-18 |
Henlix Biotech Co., Ltd. |
Przeciwciała przeciwko receptorowi naskórkowego czynnika wzrostu (EGFR)
|
KR20210047355A
(ko)
|
2014-06-03 |
2021-04-29 |
엑스바이오테크 인코포레이티드 |
스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
|
LT3151921T
(lt)
|
2014-06-06 |
2019-12-10 |
Bristol Myers Squibb Co |
Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
RU2016148616A
(ru)
|
2014-06-11 |
2018-07-18 |
Дженентек, Инк. |
Анти-lgr5 антитела и их применение
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
CA2947504A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
多重特異的NKp46結合タンパク質
|
US11208480B2
(en)
|
2014-06-27 |
2021-12-28 |
Innate Pharma |
Multispecific antigen binding proteins
|
BR112017000130A2
(pt)
|
2014-07-11 |
2018-01-09 |
Genentech Inc |
método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
|
EP3166974A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
WO2016012468A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
|
WO2016014984A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
TW201613977A
(en)
|
2014-08-07 |
2016-04-16 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
ES2906216T3
(es)
|
2014-08-07 |
2022-04-13 |
Novartis Ag |
Anticuerpos de 4 similar a la angiopoyetina y métodos de uso
|
HRP20220738T1
(hr)
|
2014-08-11 |
2022-08-19 |
Acerta Pharma B.V. |
Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
CA2954599A1
(en)
|
2014-08-12 |
2016-02-18 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
KR102050082B1
(ko)
|
2014-08-19 |
2019-11-29 |
머크 샤프 앤드 돔 코포레이션 |
항-tigit 항체
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
KR20230172625A
(ko)
|
2014-08-28 |
2023-12-22 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
ES2830385T3
(es)
|
2014-09-12 |
2021-06-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-HER2
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
JP6730261B2
(ja)
|
2014-09-17 |
2020-07-29 |
ジェネンテック, インコーポレイテッド |
抗her2抗体を含む免疫複合体
|
RS60349B8
(sr)
|
2014-09-23 |
2022-10-31 |
Hoffmann La Roche |
Postupak upotrebe anti-cd79b imunokonjugata
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016054598A2
(en)
|
2014-10-03 |
2016-04-07 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
CN107073116A
(zh)
|
2014-10-23 |
2017-08-18 |
依奈特制药公司 |
使用抗nkg2a试剂治疗癌症
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
US20160161485A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
CN114381521A
(zh)
|
2014-11-03 |
2022-04-22 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
KR20170080675A
(ko)
|
2014-11-05 |
2017-07-10 |
제넨테크, 인크. |
항-fgfr2/3 항체 및 이의 이용 방법
|
WO2016073282A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MX2017005148A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
US10093730B2
(en)
|
2014-11-10 |
2018-10-09 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
TN2017000173A1
(en)
|
2014-11-14 |
2018-10-19 |
Novartis Ag |
Antibody drug conjugates
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
PL3221355T3
(pl)
|
2014-11-20 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Cd73に対する抗体およびその使用
|
WO2016081746A2
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
NZ732144A
(en)
|
2014-11-26 |
2020-04-24 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
MX2017007231A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
|
RU2731055C2
(ru)
|
2014-12-03 |
2020-08-28 |
Дженентек, Инк. |
Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
LT3227336T
(lt)
|
2014-12-05 |
2019-09-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b antikūnai ir jų naudojimo būdai
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
RU2017120039A
(ru)
|
2014-12-10 |
2019-01-10 |
Дженентек, Инк. |
Антитела к рецепторам гематоэнцефалического барьера и способы их применения
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
US10858671B2
(en)
|
2014-12-12 |
2020-12-08 |
University Of Copenhagen |
N-glycosylation
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
WO2016097865A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
AR103162A1
(es)
|
2014-12-19 |
2017-04-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y métodos para su uso
|
CN107108726A
(zh)
|
2014-12-19 |
2017-08-29 |
中外制药株式会社 |
抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
CN107207594B
(zh)
|
2014-12-23 |
2019-05-07 |
百时美施贵宝公司 |
针对tigit的抗体
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
KR20170128234A
(ko)
|
2015-01-16 |
2017-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1에 특이적인 항체 및 키메라 항원 수용체
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
2種以上の抗c5抗体の組み合わせおよび使用方法
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
SG11201706014PA
(en)
|
2015-02-05 |
2017-08-30 |
Chugai Pharmaceutical Co Ltd |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
WO2016130539A2
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
ES2786651T3
(es)
|
2015-02-19 |
2020-10-13 |
Compugen Ltd |
Anticuerpos anti-PVRIG y métodos de uso
|
WO2016134335A2
(en)
|
2015-02-19 |
2016-08-25 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
EP3261665A1
(en)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
AU2016233398A1
(en)
|
2015-03-16 |
2017-09-07 |
F. Hoffmann-La Roche Ag |
Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
EP3271389B8
(en)
|
2015-03-20 |
2020-04-22 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to gp120 and their use
|
EP3072957B1
(en)
|
2015-03-23 |
2019-07-10 |
Lonza Ltd |
Methods for controlling protein glycosylation
|
PL3273992T3
(pl)
|
2015-03-23 |
2020-11-16 |
Jounce Therapeutics, Inc. |
Przeciwciała przeciwko icos
|
WO2016153572A1
(en)
|
2015-03-25 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
BR112017020915A2
(pt)
|
2015-04-02 |
2018-07-10 |
Intervet Int Bv |
?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
|
US20180208658A1
(en)
|
2015-04-03 |
2018-07-26 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
KR102451786B1
(ko)
|
2015-04-28 |
2022-10-05 |
미쓰비시 타나베 파마 코퍼레이션 |
RGMa 결합 단백질 및 그 사용
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
BR112017023849A2
(pt)
|
2015-05-07 |
2018-07-17 |
Agenus Inc. |
anticorpos anti-ox40 e métodos de uso dos mesmos
|
EP4238994A3
(en)
|
2015-05-11 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
CN107667119A
(zh)
|
2015-05-12 |
2018-02-06 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
JP6587696B2
(ja)
*
|
2015-05-13 |
2019-10-09 |
ズムトール バイオロジクス、インコーポレイテッド |
アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
|
JP6770533B2
(ja)
|
2015-05-22 |
2020-10-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Cath−Dの触媒活性と、そのLRP1レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
RU2715597C2
(ru)
|
2015-05-29 |
2020-03-02 |
Эббви Инк. |
Антитела к cd40 и способы их применения
|
EP3763827A1
(en)
|
2015-05-29 |
2021-01-13 |
F. Hoffmann-La Roche AG |
Pd-l1 promoter methylation in cancer
|
KR20180010264A
(ko)
|
2015-05-29 |
2018-01-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Ox40에 대한 항체 및 그의 용도
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
TWI827405B
(zh)
|
2015-06-05 |
2023-12-21 |
美商建南德克公司 |
抗-tau抗體及使用方法
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
AU2016274767B2
(en)
|
2015-06-09 |
2022-05-19 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
|
TW201709934A
(zh)
|
2015-06-15 |
2017-03-16 |
建南德克公司 |
抗體及免疫結合物
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
SI3310814T1
(sl)
|
2015-06-16 |
2023-11-30 |
F. Hoffmann - La Roche Ag |
HUMANIZIRANA IN AFINITETNO DOZORELA PROTITELESA PROTI FcRH5 IN METODE ZA NJIHOVO UPORABO
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
EP3310385A4
(en)
|
2015-06-17 |
2018-12-19 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
CN107787331B
(zh)
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CA2990518A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
BR112017024610A2
(pt)
|
2015-06-24 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
anticorpos para receptor antitransferrina com afinidade especificada
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
CA3162816A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
EP4180455A1
(en)
|
2015-06-29 |
2023-05-17 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
KR20180021864A
(ko)
|
2015-06-29 |
2018-03-05 |
제넨테크, 인크. |
장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
ES2896055T3
(es)
|
2015-07-13 |
2022-02-23 |
Compugen Ltd |
Composiciones de HIDE1 y métodos
|
US10709697B2
(en)
|
2015-07-16 |
2020-07-14 |
Emory University |
Bis-amines, compositions, and uses related to CXCR4 inhibition
|
WO2017021450A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Ag |
Monoclonal antibodies against bcma
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
JP6914919B2
(ja)
|
2015-08-28 |
2021-08-04 |
ジェネンテック, インコーポレイテッド |
抗ヒプシン抗体及びその使用
|
IL257798B1
(en)
|
2015-09-02 |
2024-06-01 |
Immutep Sas |
Antibodies against LAG-3
|
EP3347377B1
(en)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
TWI751300B
(zh)
|
2015-09-18 |
2022-01-01 |
日商中外製藥股份有限公司 |
Il-8 結合抗體及其用途
|
AU2016328357B2
(en)
|
2015-09-22 |
2023-03-02 |
Ventana Medical Systems, Inc. |
Anti-OX40 antibodies and diagnostic uses thereof
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
SI3354729T1
(sl)
|
2015-09-24 |
2024-05-31 |
Daiichi Sankyo Company, Limited |
Protitelesa anti-garp
|
RU2757135C2
(ru)
|
2015-09-24 |
2021-10-11 |
АБВИТРО ЭлЭлСи |
Композиции антител к вич и способы их применения
|
IL298355A
(en)
|
2015-09-25 |
2023-01-01 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43023A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
WO2017062682A2
(en)
|
2015-10-06 |
2017-04-13 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
US10968277B2
(en)
|
2015-10-22 |
2021-04-06 |
Jounce Therapeutics, Inc. |
Gene signatures for determining ICOS expression
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
EP3368568B1
(en)
|
2015-10-29 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
BR112018007703A2
(pt)
|
2015-10-30 |
2018-11-06 |
Genentech Inc |
anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
|
EP4011911A1
(en)
|
2015-11-03 |
2022-06-15 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Neutralizing antibodies to hiv-1 gp41 and their use
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
EP3377527A1
(en)
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme Corp. |
Ctla4 binders
|
JP6779997B2
(ja)
|
2015-11-18 |
2020-11-04 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Pd1/ctla4結合性物質
|
BR112018010084A2
(pt)
|
2015-11-18 |
2018-11-13 |
Merck Sharp & Dohme |
ligantes de pd1 e/ou lag3
|
SG11201803817PA
(en)
|
2015-11-19 |
2018-06-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2017091577A1
(en)
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
CN108602885B
(zh)
|
2015-11-30 |
2022-05-24 |
百时美施贵宝公司 |
抗人ip-10抗体及其用途
|
KR20210016479A
(ko)
|
2015-12-04 |
2021-02-15 |
노파르티스 아게 |
항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
IL257696B1
(en)
|
2015-12-09 |
2024-07-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
EP3399989B1
(en)
|
2015-12-16 |
2023-08-09 |
Merck Sharp & Dohme LLC |
Anti-lag3 antibodies and antigen-binding fragments
|
JP6088703B1
(ja)
|
2015-12-18 |
2017-03-01 |
中外製薬株式会社 |
抗c5抗体および使用方法
|
US20170198040A1
(en)
|
2015-12-18 |
2017-07-13 |
Novartis Ag |
ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
|
US10596257B2
(en)
|
2016-01-08 |
2020-03-24 |
Hoffmann-La Roche Inc. |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
WO2017122175A1
(en)
|
2016-01-13 |
2017-07-20 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
WO2017127764A1
(en)
|
2016-01-20 |
2017-07-27 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
NZ743881A
(en)
|
2016-02-06 |
2023-11-24 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem immunoglobulin and uses thereof
|
CN116920085A
(zh)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
JP2019511911A
(ja)
|
2016-02-17 |
2019-05-09 |
ノバルティス アーゲー |
Tgfベータ2抗体
|
EP4155415A1
(en)
|
2016-02-29 |
2023-03-29 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3423490A1
(en)
|
2016-03-01 |
2019-01-09 |
H. Hoffnabb-La Roche Ag |
Obinutuzumab and rituximab variants having reduced adcp
|
JP2019514844A
(ja)
|
2016-03-04 |
2019-06-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗cd73抗体を用いた併用療法
|
JP2019517993A
(ja)
|
2016-03-15 |
2019-06-27 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
抗mica抗体
|
MX2018010546A
(es)
|
2016-03-15 |
2019-02-20 |
Chugai Pharmaceutical Co Ltd |
Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
|
KR102438140B1
(ko)
|
2016-03-22 |
2022-08-31 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
인간화 항-클라우딘-1 항체 및 이의 용도
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
WO2017165734A1
(en)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
US11104739B2
(en)
|
2016-04-14 |
2021-08-31 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
|
KR20190003957A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암 모니터링 및 치료 방법
|
CN109789201B
(zh)
|
2016-04-15 |
2023-06-16 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
EP3443350B1
(en)
|
2016-04-15 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
JP6735355B2
(ja)
|
2016-04-15 |
2020-08-05 |
バイオアトラ、エルエルシー |
抗Axl抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用
|
CA3019588A1
(en)
|
2016-04-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Cmv neutralizing antigen binding proteins
|
EP3448887A1
(en)
|
2016-04-27 |
2019-03-06 |
Novartis AG |
Antibodies against growth differentiation factor 15 and uses thereof
|
EP3889175A1
(en)
|
2016-05-02 |
2021-10-06 |
F. Hoffmann-La Roche AG |
The contorsbody - a single chain target binder
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
EP3455252B1
(en)
|
2016-05-11 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Modified anti-tenascin antibodies and methods of use
|
AU2017263568B2
(en)
|
2016-05-13 |
2024-01-18 |
Bioatla, Llc |
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
EP3458089A1
(en)
|
2016-05-18 |
2019-03-27 |
Genmab B.V. |
Antibodies and methods of use thereof in treatment of infectious disease
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3888689A1
(en)
|
2016-06-08 |
2021-10-06 |
AbbVie Inc. |
Anti-egfr antibody drug conjugates
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019524649A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
SG10201914119TA
(en)
|
2016-06-08 |
2020-02-27 |
Abbvie Inc |
Anti-b7-h3 antibodies and antibody drug conjugates
|
JP2019521975A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗egfr抗体薬物コンジュゲート
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
PT3468997T
(pt)
|
2016-06-08 |
2023-12-07 |
Debra Zack |
Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b
|
US20200338209A1
(en)
|
2016-06-08 |
2020-10-29 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
CA3027178A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
KR20230054508A
(ko)
|
2016-06-14 |
2023-04-24 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
UY37325A
(es)
|
2016-07-14 |
2018-01-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
|
JP7316930B2
(ja)
|
2016-07-15 |
2023-07-28 |
武田薬品工業株式会社 |
形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
KR102553195B1
(ko)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
AU2017303205B2
(en)
|
2016-07-29 |
2024-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity
|
EP3490676A1
(en)
|
2016-07-29 |
2019-06-05 |
Eli Lilly and Company |
Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
JP7219207B2
(ja)
|
2016-07-29 |
2023-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
腫瘍関連マクロファージを標的化する抗体及びその使用
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
KR20190035863A
(ko)
|
2016-08-05 |
2019-04-03 |
알라코스 인크. |
암 치료를 위한 항Siglec-7 항체
|
CN116251182A
(zh)
|
2016-08-05 |
2023-06-13 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
WO2018035084A1
(en)
|
2016-08-16 |
2018-02-22 |
Epimab Biotherapeutics, Inc. |
Monovalent asymmetric tandem fab bispecific antibodies
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
EP3512883A1
(en)
|
2016-09-13 |
2019-07-24 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
DK3528838T3
(da)
|
2016-09-23 |
2023-08-28 |
Hoffmann La Roche |
Anvendelser af anti-IL-13-antistoffer til behandling af atopisk dermatitis
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
KR20190066026A
(ko)
|
2016-10-07 |
2019-06-12 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
AU2017343778A1
(en)
|
2016-10-13 |
2019-05-02 |
Massachusetts Institute Of Technology |
Antibodies that bind Zika virus envelope protein and uses thereof
|
JP7273453B2
(ja)
|
2016-10-14 |
2023-05-15 |
ゼンコア インコーポレイテッド |
IL-15/IL-15RアルファFc融合タンパク質およびPD-1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
|
CN109863175A
(zh)
|
2016-10-21 |
2019-06-07 |
依奈特制药公司 |
用抗-kir3dl2药剂进行的治疗
|
US11186635B2
(en)
|
2016-10-25 |
2021-11-30 |
Institut National De La Santé Et De La Recherché Médical (Inserm) |
Monoclonal antibodies binding to the CD160 transmembrane isoform
|
WO2018081578A1
(en)
|
2016-10-28 |
2018-05-03 |
Astute Medical, Inc. |
Use of antibodies to timp-2 for the improvement of renal function
|
MX2019004779A
(es)
|
2016-10-28 |
2019-08-12 |
Toray Industries |
Composicion farmaceutica para tratamiento y/o prevencion de cancer.
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
KR20190070977A
(ko)
|
2016-11-01 |
2019-06-21 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
WO2018085358A1
(en)
|
2016-11-02 |
2018-05-11 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
CA3041183A1
(en)
|
2016-11-02 |
2018-05-11 |
Engmab Sarl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
US11117968B2
(en)
|
2016-11-03 |
2021-09-14 |
Bristol-Myers Squibb Company |
Activatable anti-CTLA-4 antibodies and uses thereof
|
EP3538546A1
(en)
|
2016-11-14 |
2019-09-18 |
Novartis AG |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
US20210283249A1
(en)
|
2016-11-16 |
2021-09-16 |
Eli Lilly And Company |
Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
BR112019010349A2
(pt)
|
2016-11-23 |
2019-10-08 |
Bioverativ Therapeutics Inc |
Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
EP3551655A2
(en)
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau antibodies and methods of their use
|
CN118165104A
(zh)
|
2016-12-07 |
2024-06-11 |
基因泰克公司 |
抗tau抗体和使用方法
|
KR20190095921A
(ko)
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
|
SG10201912575RA
(en)
|
2016-12-12 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
CA3048174A1
(en)
|
2016-12-22 |
2018-06-28 |
Daiichi Sankyo Company, Limited |
Anti-cd3 antibody and molecules comprising the antibody
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
EP3559047A1
(en)
|
2016-12-23 |
2019-10-30 |
Novartis AG |
Factor xi antibodies and methods of use
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
KR20190104048A
(ko)
|
2017-01-06 |
2019-09-05 |
이오반스 바이오테라퓨틱스, 인크. |
종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
|
JP2020503351A
(ja)
|
2017-01-06 |
2020-01-30 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
|
CA3039772C
(en)
|
2017-01-06 |
2020-08-25 |
Eutilex Co., Ltd. |
Anti-human 4-1bb antibodies and uses thereof
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
SG11201906554RA
(en)
|
2017-01-17 |
2019-08-27 |
Daiichi Sankyo Co Ltd |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
WO2018139404A1
(ja)
|
2017-01-24 |
2018-08-02 |
協和発酵キリン株式会社 |
放射線障害の治療又は予防剤並びに治療又は予防方法
|
MX2019009358A
(es)
|
2017-02-07 |
2019-12-02 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo.
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
MX2019009346A
(es)
|
2017-02-10 |
2019-10-02 |
Genmab Bv |
Variantes de polipeptidos y usos de los mismos.
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2018146549A1
(en)
|
2017-02-10 |
2018-08-16 |
Eutilex Co., Ltd. |
IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
|
EP3579872A1
(en)
|
2017-02-10 |
2019-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
CN110506057B
(zh)
|
2017-02-17 |
2023-09-29 |
百时美施贵宝公司 |
Alpha突触核蛋白抗体及其应用
|
BR112019017695A2
(pt)
|
2017-02-28 |
2020-04-07 |
Bristol-Myers Squibb Company |
uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina
|
JP7181181B2
(ja)
|
2017-02-28 |
2022-11-30 |
第一三共株式会社 |
抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
JP6430082B1
(ja)
|
2017-03-02 |
2018-11-28 |
学校法人 聖マリアンナ医科大学 |
低用量抗ccr4抗体を用いたhtlv−1関連脊髄症の予防または治療剤
|
TWI839327B
(zh)
|
2017-03-22 |
2024-04-21 |
美商建南德克公司 |
用於治療眼部病症之最佳化之抗體組合物
|
KR20240014600A
(ko)
|
2017-03-24 |
2024-02-01 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
CN110494446A
(zh)
|
2017-03-28 |
2019-11-22 |
基因泰克公司 |
治疗神经退行性疾病的方法
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
CA3058134A1
(en)
|
2017-04-13 |
2018-10-18 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
KR20200005540A
(ko)
|
2017-04-14 |
2020-01-15 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
PE20200150A1
(es)
|
2017-04-21 |
2020-01-17 |
Genentech Inc |
Uso de antagonistas de klk5 para el tratamiento de una enfermedad
|
AU2018258049A1
(en)
|
2017-04-26 |
2019-12-12 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
CN110831628A
(zh)
|
2017-05-05 |
2020-02-21 |
爱乐科斯公司 |
用于治疗过敏性眼病的方法和组合物
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2018209125A1
(en)
|
2017-05-10 |
2018-11-15 |
Fred Hutchinson Cancer Research Center |
Epstein barr virus antibodies, vaccines, and uses of the same
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
CN111094335B
(zh)
|
2017-05-15 |
2022-08-23 |
罗切斯特大学 |
广泛中和的抗流感单克隆抗体及其用途
|
CA3062177A1
(en)
|
2017-05-16 |
2018-11-22 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
KR20200031571A
(ko)
|
2017-05-29 |
2020-03-24 |
가마맵스 파마 |
암 연관 면역억제의 억제제
|
SG10202111336RA
(en)
|
2017-06-01 |
2021-11-29 |
Compugen Ltd |
Triple combination antibody therapies
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
US11912775B2
(en)
|
2017-07-18 |
2024-02-27 |
Kyowa Kirin Co., Ltd. |
Anti-human CCR1 monoclonal antibody
|
MX2020000604A
(es)
|
2017-07-21 |
2020-09-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
AU2018308364C1
(en)
|
2017-07-26 |
2023-02-16 |
Forty Seven, Inc. |
Anti-SIRP-alpha antibodies and related methods
|
AU2018307292A1
(en)
|
2017-07-27 |
2020-02-20 |
Daiichi Sankyo Company, Limited |
Anti-CD147 antibody
|
CN110944667B
(zh)
|
2017-08-23 |
2024-08-27 |
第一三共株式会社 |
抗体-药物缀合物制剂及其冻干
|
US11306144B2
(en)
|
2017-08-25 |
2022-04-19 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
KR20240018674A
(ko)
|
2017-08-31 |
2024-02-13 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 신규 제조 방법
|
EP3677589A4
(en)
|
2017-08-31 |
2021-04-21 |
Daiichi Sankyo Company, Limited |
IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
AU2018342527B2
(en)
|
2017-09-29 |
2024-06-27 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
EP4215543A3
(en)
|
2017-10-03 |
2023-10-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
JP7384668B2
(ja)
|
2017-10-05 |
2023-11-21 |
第一三共株式会社 |
細胞傷害性t細胞枯渇用組成物
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
CN111372950A
(zh)
|
2017-10-12 |
2020-07-03 |
免疫苏醒公司 |
Vegfr-抗体轻链融合蛋白
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
EP3703688A2
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
CA3081854A1
(en)
|
2017-11-08 |
2019-05-16 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody which binds to cd40 and epcam
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
CA3079363A1
(en)
|
2017-11-21 |
2019-05-31 |
Innate Pharma |
Multispecific antigen binding proteins
|
KR20200087236A
(ko)
|
2017-11-22 |
2020-07-20 |
노파르티스 아게 |
항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
SG11202003930YA
(en)
|
2017-12-01 |
2020-05-28 |
Pfizer |
Anti-cxcr5 antibodies and compositions and uses thereof
|
WO2019106193A1
(en)
|
2017-12-01 |
2019-06-06 |
University Of Copenhagen |
Peptide hormone with one or more o-glycans
|
JP2021508439A
(ja)
|
2017-12-01 |
2021-03-11 |
ノバルティス アーゲー |
ポリオーマウイルス中和抗体
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
US10723798B2
(en)
|
2017-12-22 |
2020-07-28 |
Jounce Therapeutics, Inc. |
Antibodies to LILRB2
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
SG11202005273XA
(en)
|
2017-12-28 |
2020-07-29 |
Nanjing Legend Biotech Co Ltd |
Antibodies and variants thereof against pd-l1
|
AU2018396970A1
(en)
|
2017-12-28 |
2020-08-13 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
US11891439B2
(en)
|
2017-12-28 |
2024-02-06 |
Astute Medical, Inc. |
Antibodies and assays for CCL14
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
WO2019134981A1
(en)
|
2018-01-05 |
2019-07-11 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CN111886255A
(zh)
|
2018-01-12 |
2020-11-03 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
JP7366908B2
(ja)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Pd-1に対する単一ドメイン抗体及びその変異体
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
BR112020015016A2
(pt)
|
2018-01-26 |
2020-12-29 |
Genentech, Inc. |
Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
|
TWI835772B
(zh)
|
2018-01-26 |
2024-03-21 |
美商建南德克公司 |
Il-22fc融合蛋白及使用方法
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
TW202330621A
(zh)
|
2018-02-01 |
2023-08-01 |
大陸商信達生物製藥(蘇州)有限公司 |
全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用
|
JP2021512120A
(ja)
|
2018-02-02 |
2021-05-13 |
バイオ−テクネ コーポレーション |
Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
EP3749362A1
(en)
|
2018-02-09 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
EP3752600A1
(en)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
WO2019158645A1
(en)
|
2018-02-14 |
2019-08-22 |
Abba Therapeutics Ag |
Anti-human pd-l2 antibodies
|
MX2020008502A
(es)
|
2018-02-21 |
2020-09-25 |
Genentech Inc |
Dosis para el tratamiento con proteinas de fusion il-22 fc.
|
BR112020016986A2
(pt)
|
2018-02-21 |
2021-03-02 |
Five Prime Therapeutics, Inc. |
formulações de anticorpo contra b7-h4
|
MA51902A
(fr)
|
2018-02-21 |
2021-05-26 |
Five Prime Therapeutics Inc |
Schémas posologiques d'anticorps b7-h4
|
EP3755713A1
(en)
|
2018-02-21 |
2020-12-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック, インコーポレイテッド |
抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬
|
AU2019228600A1
(en)
|
2018-03-02 |
2020-09-24 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
KR20200128017A
(ko)
|
2018-03-05 |
2020-11-11 |
각코우호우징 사이타마이카다이가쿠 |
이소성 골화의 치료 또는 예방을 위한 의약 조성물
|
KR20200130831A
(ko)
|
2018-03-14 |
2020-11-20 |
베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 |
항-클라우딘 18.2 항체
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
CN111971304A
(zh)
|
2018-03-21 |
2020-11-20 |
戊瑞治疗有限公司 |
在酸性pH结合至VISTA的抗体
|
SG11202008767XA
(en)
|
2018-03-23 |
2020-10-29 |
Bristol Myers Squibb Co |
Antibodies against mica and/or micb and uses thereof
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
MX2020009862A
(es)
|
2018-03-30 |
2020-10-08 |
Toray Industries |
Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
WO2019210848A1
(en)
|
2018-05-03 |
2019-11-07 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
|
CN112839958A
(zh)
|
2018-05-03 |
2021-05-25 |
根马布私人有限公司 |
抗体变体组合及其用途
|
ES2955511T3
(es)
|
2018-05-14 |
2023-12-04 |
Werewolf Therapeutics Inc |
Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
|
MX2020012252A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
|
PT3794042T
(pt)
|
2018-05-18 |
2024-06-14 |
Daiichi Sankyo Co Ltd |
Conjugado anticorpo-fármaco anti-muc1-exatecano
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
CA3101906A1
(en)
|
2018-05-28 |
2019-12-05 |
Daiichi Sankyo Company, Limited |
Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
CN118126183A
(zh)
|
2018-05-31 |
2024-06-04 |
第一三共株式会社 |
抗人tlr7抗体
|
CN112165974A
(zh)
|
2018-05-31 |
2021-01-01 |
诺华股份有限公司 |
乙型肝炎抗体
|
US11987629B2
(en)
|
2018-06-01 |
2024-05-21 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
EP3802599B1
(en)
|
2018-06-03 |
2023-12-20 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
JP7511308B2
(ja)
|
2018-06-18 |
2024-07-05 |
ユーリカ セラピューティックス, インコーポレイテッド |
前立腺特異的膜抗原(psma)を標的とする構築物及びその使用
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
CA3104997A1
(en)
|
2018-06-26 |
2020-01-02 |
Kyowa Kirin Co., Ltd. |
Antibody binding to chondroitin sulfate proteoglycan 5
|
WO2020004492A1
(ja)
|
2018-06-26 |
2020-01-02 |
協和キリン株式会社 |
Cell Adhesion Molecule3に結合する抗体
|
BR112020026724A2
(pt)
|
2018-07-02 |
2021-03-30 |
Amgen Inc. |
Proteína de ligação ao antígeno anti-steap1
|
SG11202100096XA
(en)
|
2018-07-09 |
2021-02-25 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
US20240254252A1
(en)
|
2018-07-13 |
2024-08-01 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
BR112020026432A2
(pt)
|
2018-07-13 |
2021-03-23 |
Genmab A/S |
variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
US11279758B2
(en)
|
2018-07-20 |
2022-03-22 |
Surface Oncology, Inc. |
Anti-CD112R compositions and methods
|
EP3828206A4
(en)
|
2018-07-25 |
2022-04-20 |
Daiichi Sankyo Company, Limited |
METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE
|
US20210290777A1
(en)
|
2018-07-31 |
2021-09-23 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
WO2020027330A1
(ja)
|
2018-08-03 |
2020-02-06 |
中外製薬株式会社 |
互いに連結された2つの抗原結合ドメインを含む抗原結合分子
|
BR112021001750A2
(pt)
|
2018-08-06 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
composição farmacêutica
|
EP3608674A1
(en)
|
2018-08-09 |
2020-02-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
US20210324099A1
(en)
|
2018-08-10 |
2021-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cd137 antigen-binding molecule and utilization thereof
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
KR20210057053A
(ko)
|
2018-08-23 |
2021-05-20 |
씨젠 인크. |
항-tigit 항체
|
CN112739826A
(zh)
|
2018-08-23 |
2021-04-30 |
第一三共株式会社 |
抗体-药物缀合物的敏感性标志物
|
WO2020047389A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
WO2020056170A1
(en)
|
2018-09-12 |
2020-03-19 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
KR20210061341A
(ko)
|
2018-09-13 |
2021-05-27 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
신규한 lilrb4 항체 및 이의 용도
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
JPWO2020059772A1
(ja)
|
2018-09-20 |
2021-08-30 |
第一三共株式会社 |
抗her3抗体−薬物コンジュゲート投与によるher3変異がんの治療
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
JP7475336B2
(ja)
|
2018-09-21 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
WO2020067541A1
(ja)
|
2018-09-28 |
2020-04-02 |
協和キリン株式会社 |
抗体組成物
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
MX2021003766A
(es)
|
2018-10-05 |
2021-05-27 |
Five Prime Therapeutics Inc |
Formulaciones de anticuerpos anti-fgfr2.
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
WO2020081497A1
(en)
|
2018-10-15 |
2020-04-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
AU2019377422A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
US20220025058A1
(en)
|
2018-11-06 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
TW202031298A
(zh)
|
2018-11-14 |
2020-09-01 |
日商第一三共股份有限公司 |
抗cdh6抗體-吡咯并苯二氮呯衍生物結合物
|
EA202191058A1
(ru)
|
2018-11-16 |
2021-10-07 |
Мемориал Слоун Кеттеринг Кэнсер Сентр |
Антитела против муцина-16 и способы их применения
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
CA3121265A1
(en)
|
2018-12-05 |
2020-06-11 |
Genentech, Inc. |
Diagnostic methods and compositions for cancer immunotherapy
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
CA3122946A1
(en)
|
2018-12-11 |
2020-06-18 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with parp inhibitor
|
US20220064260A1
(en)
|
2018-12-14 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
CN113227131A
(zh)
|
2018-12-20 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
PE20211295A1
(es)
|
2018-12-21 |
2021-07-20 |
23Andme Inc |
Anticuerpos anti il-36 y procedimientos de uso de estos
|
MX2021007768A
(es)
|
2018-12-26 |
2021-08-24 |
Xilio Dev Inc |
Anticuerpos anti-ctla4 y metodos de uso de los mismos.
|
TW202039581A
(zh)
|
2018-12-28 |
2020-11-01 |
日商協和麒麟股份有限公司 |
與TfR結合之雙專一性抗體
|
EP3902830A1
(en)
|
2018-12-30 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Anti-rabbit cd19 antibodies and methods of use
|
WO2020146740A1
(en)
|
2019-01-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
EP3911678A1
(en)
|
2019-01-14 |
2021-11-24 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
CN109762067B
(zh)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|
EP3914622A1
(en)
|
2019-01-22 |
2021-12-01 |
Bristol-Myers Squibb Company |
Antibodies against il-7r alpha subunit and uses thereof
|
CN113614107A
(zh)
|
2019-01-23 |
2021-11-05 |
Encefa公司 |
Cd31竞争剂及其用途
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
AR119683A1
(es)
|
2019-01-29 |
2022-01-05 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)
|
MX2021010313A
(es)
|
2019-02-27 |
2021-09-23 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
|
WO2020180733A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
TW202101000A
(zh)
|
2019-03-08 |
2021-01-01 |
美商建南德克公司 |
用於偵測且量化膜相關蛋白之方法
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
|
TW202102228A
(zh)
|
2019-03-25 |
2021-01-16 |
日商第一三共股份有限公司 |
抗體-吡咯并苯二氮呯衍生物結合物
|
CA3134403A1
(en)
|
2019-03-25 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
BR112021017350A2
(pt)
|
2019-03-27 |
2021-11-16 |
Daiichi Sankyo Co Ltd |
Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
JP2022529939A
(ja)
|
2019-04-18 |
2022-06-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
低pHで結合するために特異性が増強されたイピリムマブバリアント
|
US20220143094A1
(en)
|
2019-04-19 |
2022-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
EP3962523A2
(en)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
EP3968993A1
(en)
|
2019-05-14 |
2022-03-23 |
F. Hoffmann-La Roche AG |
Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
|
JP2022532217A
(ja)
|
2019-05-14 |
2022-07-13 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
分離部分及びその使用方法
|
CA3140385A1
(en)
|
2019-05-15 |
2020-11-19 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody binding to cd40 and fap
|
JP7502281B2
(ja)
|
2019-05-15 |
2024-06-18 |
協和キリン株式会社 |
Cd40とgpc3に結合するバイスペシフィック抗体
|
WO2020236841A2
(en)
|
2019-05-20 |
2020-11-26 |
Novartis Ag |
Antibody drug conjugates having linkers comprising hydrophilic groups
|
CN114630838A
(zh)
|
2019-05-20 |
2022-06-14 |
法国国家健康和医学研究院 |
新的抗cd25抗体
|
JOP20210309A1
(ar)
|
2019-05-21 |
2023-01-30 |
Novartis Ag |
جزيئات ربط بـ cd19 واستخدامتها
|
US20220396631A1
(en)
|
2019-05-21 |
2022-12-15 |
Lu HUANG |
Trispecific binding molecules against bcma and uses thereof
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
JP2022533432A
(ja)
|
2019-05-23 |
2022-07-22 |
エイシー イミューン ソシエテ アノニム |
抗tdp-43結合分子およびその使用
|
JP2022534725A
(ja)
|
2019-05-29 |
2022-08-03 |
第一三共株式会社 |
抗体薬物複合体の用量
|
PE20220489A1
(es)
|
2019-06-12 |
2022-04-07 |
Novartis Ag |
Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso
|
JP2022539178A
(ja)
|
2019-06-26 |
2022-09-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Il1rap結合タンパク質
|
KR20220031054A
(ko)
|
2019-07-02 |
2022-03-11 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Egfrviii에 결합하는 단일클론 항체 및 이의 용도
|
CN114341187A
(zh)
|
2019-07-12 |
2022-04-12 |
中外制药株式会社 |
抗突变型fgfr3抗体及其用途
|
AU2020312686A1
(en)
|
2019-07-15 |
2022-02-03 |
Intervet International B.V. |
Caninized antibodies against canine CTLA-4
|
AU2020312687A1
(en)
|
2019-07-15 |
2022-01-27 |
Intervet International B.V. |
Caninized antibodies to human and canine CTLA-4
|
US20220251234A1
(en)
|
2019-07-16 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
JP2022542863A
(ja)
|
2019-07-24 |
2022-10-07 |
ハー・ルンドベック・アクチエゼルスカベット |
抗mGluR5抗体及びその使用
|
EP4008350A4
(en)
|
2019-07-26 |
2023-06-14 |
Saitama Medical University |
ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
|
BR112022001575A2
(pt)
|
2019-07-29 |
2022-04-19 |
Compugen Ltd |
Formulações de anticorpos anti-pvrig e usos dos mesmos
|
US20220289859A1
(en)
|
2019-08-06 |
2022-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmacuetical Compositions and Related Methods
|
CN114641490B
(zh)
|
2019-08-06 |
2023-06-06 |
新旭生技股份有限公司 |
结合至病理性tau种类的抗体及其用途
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
BR112022004831A2
(pt)
|
2019-09-19 |
2022-06-07 |
Bristol Myers Squibb Co |
Anticorpos que se ligam a vista em ph ácido
|
CN114423454A
(zh)
|
2019-09-20 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体的给药
|
TW202126688A
(zh)
|
2019-09-27 |
2021-07-16 |
瑞典商阿斯特捷利康公司 |
使用貝那利珠單抗治療遲發性氣喘之方法
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック, インコーポレイテッド |
薬抗tigit及び抗pd-l1アンタゴニスト抗体を用いた処置のための投薬
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
TW202122114A
(zh)
|
2019-10-18 |
2021-06-16 |
美商建南德克公司 |
使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
|
CA3160162A1
(en)
|
2019-11-04 |
2021-05-14 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
MX2022005400A
(es)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
KR20220098046A
(ko)
|
2019-11-20 |
2022-07-08 |
추가이 세이야쿠 가부시키가이샤 |
항체 함유 제제
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
CA3163897A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
WO2021123094A1
(en)
|
2019-12-20 |
2021-06-24 |
Intervet International B.V. |
Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
|
US20230075422A1
(en)
|
2019-12-20 |
2023-03-09 |
Bristol-Myers Squibb Company |
Use of fucosylation inhibitor for producing afucosylated antibody
|
BR112022011797A2
(pt)
|
2019-12-20 |
2022-08-30 |
Intervet Int Bv |
Anticorpos contra receptor alfa de interleucina-4 canino
|
CN110964090B
(zh)
*
|
2019-12-26 |
2021-02-19 |
江南大学 |
一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
|
AR120898A1
(es)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
Agente para tratar o prevenir neuromielitis óptica en fase aguda
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
CR20220357A
(es)
|
2019-12-27 |
2022-08-24 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
TW202140555A
(zh)
|
2020-01-15 |
2021-11-01 |
國立大學法人大阪大學 |
失智症之預防或治療劑
|
CA3165660A1
(en)
|
2020-01-16 |
2021-07-22 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MX2022009391A
(es)
|
2020-01-31 |
2022-09-26 |
Genentech Inc |
Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
CA3165319A1
(en)
|
2020-01-31 |
2021-08-05 |
Vincent K. Tuohy |
Anti-mullerian hormone receptor 2 antibodies and methods of use
|
EP4100435A1
(en)
|
2020-02-05 |
2022-12-14 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
TW202140561A
(zh)
|
2020-02-14 |
2021-11-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
WO2021168292A1
(en)
|
2020-02-20 |
2021-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
KR20220147642A
(ko)
|
2020-02-27 |
2022-11-03 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Il4r에 결합하는 항체 및 이의 용도
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
CN115151573A
(zh)
|
2020-02-28 |
2022-10-04 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体、多特异性抗体及其用途
|
JPWO2021182573A1
(US20050276830A1-20051215-C00018.png)
|
2020-03-12 |
2021-09-16 |
|
|
EP4119158A4
(en)
|
2020-03-12 |
2024-05-08 |
Toray Industries, Inc. |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
JPWO2021182574A1
(US20050276830A1-20051215-C00018.png)
|
2020-03-12 |
2021-09-16 |
|
|
WO2021182572A1
(ja)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
KR20220153621A
(ko)
|
2020-03-12 |
2022-11-18 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
PE20230252A1
(es)
|
2020-03-13 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos de estos
|
CR20220524A
(es)
|
2020-03-19 |
2022-12-02 |
Genentech Inc |
Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso
|
PE20230821A1
(es)
|
2020-03-23 |
2023-05-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-ccr8 para el tratamiento del cancer
|
KR20220157445A
(ko)
|
2020-03-24 |
2022-11-29 |
제넨테크, 인크. |
Tie2-결합제 및 사용방법
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
MX2022010751A
(es)
|
2020-03-30 |
2022-09-23 |
Univ Mie |
Anticuerpo biespecifico.
|
EP4126934A1
(en)
|
2020-04-01 |
2023-02-08 |
University of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
KR20220161337A
(ko)
|
2020-04-01 |
2022-12-06 |
쿄와 기린 가부시키가이샤 |
항체 조성물
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
JP2023522930A
(ja)
|
2020-04-24 |
2023-06-01 |
ジェネンテック, インコーポレイテッド |
抗CD79b免疫抱合体の使用方法
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
TW202216757A
(zh)
|
2020-04-28 |
2022-05-01 |
美國洛克菲勒大學 |
中和性抗sars-cov-2抗體及其使用方法
|
BR112022022045A2
(pt)
|
2020-04-30 |
2023-01-10 |
Sairopa B V |
Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
|
IL297830A
(en)
|
2020-05-03 |
2023-01-01 |
Levena Suzhou Biopharma Co Ltd |
Anti-drug compounds (adcs) comprising an anti-trop-2 antibody, compounds comprising such adcs, as well as methods for their production and use
|
IL298075A
(en)
|
2020-05-12 |
2023-01-01 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
st2 antigen binding protein
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3182150A1
(en)
|
2020-05-17 |
2021-11-25 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
BR112022024149A2
(pt)
|
2020-05-26 |
2023-02-07 |
Regeneron Pharma |
Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
|
CN113993900B
(zh)
|
2020-05-27 |
2023-08-04 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别神经生长因子的抗体及其用途
|
BR112022024339A2
(pt)
|
2020-05-29 |
2022-12-27 |
23Andme Inc |
Anticorpos anti cd200r1 e métodos de uso dos mesmos
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
BR112022024629A2
(pt)
|
2020-06-02 |
2023-02-23 |
Dynamicure Biotechnology Llc |
Construtos anti-cd93 e seus usos
|
AU2021283349A1
(en)
|
2020-06-03 |
2023-02-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
US20230235040A1
(en)
|
2020-06-22 |
2023-07-27 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
WO2021259227A1
(zh)
|
2020-06-23 |
2021-12-30 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
JP2023528535A
(ja)
|
2020-06-25 |
2023-07-04 |
メルク・シャープ・アンド・ドーム・エルエルシー |
セリン413においてリン酸化されたタウを標的化する高親和性抗体
|
AU2021298632A1
(en)
|
2020-06-30 |
2023-01-19 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-CD70 antibody and application thereof
|
IL299803A
(en)
|
2020-07-17 |
2023-03-01 |
Daiichi Sankyo Co Ltd |
Production method for antibody-drug conjugate
|
AU2021312537A1
(en)
|
2020-07-20 |
2023-03-09 |
Daiichi Sankyo Company, Limited |
Combination of (anti-HER2 antibody)-drug conjugate and her dimerization inhibitor
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
US20230322935A1
(en)
|
2020-07-29 |
2023-10-12 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
EP4192854A1
(en)
|
2020-08-07 |
2023-06-14 |
Genentech, Inc. |
Flt3 ligand fusion proteins and methods of use
|
TW202221025A
(zh)
|
2020-08-10 |
2022-06-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19的sars—cov—2抗體
|
US20230416364A1
(en)
|
2020-08-13 |
2023-12-28 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
JP2023537761A
(ja)
|
2020-08-14 |
2023-09-05 |
エイシー イミューン ソシエテ アノニム |
ヒト化抗tdp-43結合分子およびその使用
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
KR20230048233A
(ko)
|
2020-09-01 |
2023-04-11 |
추가이 세이야쿠 가부시키가이샤 |
Il-31 안타고니스트를 유효 성분으로서 함유하는, 투석 소양증의 예방용 및/또는 치료용 의약 조성물
|
MX2023002901A
(es)
|
2020-09-14 |
2023-06-01 |
Ichnos Sciences SA |
Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos.
|
WO2022069940A1
(en)
|
2020-09-30 |
2022-04-07 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
CA3197662A1
(en)
|
2020-09-30 |
2022-04-07 |
Dren Bio, Inc. |
Anti-cd94 antibodies and methods of use thereof
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
MX2023004054A
(es)
|
2020-10-07 |
2023-06-29 |
Dren Bio Inc |
Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
|
US11926667B2
(en)
|
2020-10-13 |
2024-03-12 |
Janssen Biotech, Inc. |
Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
JP2023545566A
(ja)
|
2020-10-20 |
2023-10-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法
|
CA3192306A1
(en)
|
2020-10-20 |
2022-04-28 |
Burkhard Ludewig |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
EP4232822A2
(en)
|
2020-10-26 |
2023-08-30 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
KR20230095113A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
|
AU2021374592A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
KR20230097156A
(ko)
|
2020-11-06 |
2023-06-30 |
브리스톨-마이어스 스큅 컴퍼니 |
단독요법으로서 비-푸코실화 항-ctla-4 항체의 투약 및 투여
|
AU2021374083A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
KR20230106645A
(ko)
|
2020-11-11 |
2023-07-13 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 항 SIRPα 항체의 조합
|
US20230398230A1
(en)
|
2020-11-12 |
2023-12-14 |
Daiichi Sankyo Company, Limited |
Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
|
AU2021380966A1
(en)
|
2020-11-20 |
2023-06-22 |
Alderaan Biotechnology |
Anti-cd25 antibodies
|
WO2022106663A1
(en)
|
2020-11-20 |
2022-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd25 antibodies
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
JP2024500920A
(ja)
|
2020-12-23 |
2024-01-10 |
カンタージア アクチエボラーグ |
抗il1rap抗体
|
CN114685669A
(zh)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
结合trop2的抗体及其用途
|
CA3203382A1
(en)
|
2020-12-31 |
2022-07-07 |
Adrian Emanual Wells |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
EP4276113A1
(en)
|
2021-01-08 |
2023-11-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antibody specifically binding to cd47 and antigen-binding fragment thereof
|
CN116710482A
(zh)
|
2021-01-08 |
2023-09-05 |
北京韩美药品有限公司 |
特异性结合4-1bb的抗体及其抗原结合片段
|
TW202245844A
(zh)
|
2021-01-13 |
2022-12-01 |
紀念斯隆凱特琳癌症中心 |
抗dll3抗體-藥物結合物
|
MX2023008261A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
|
EP4277926A1
(en)
|
2021-01-15 |
2023-11-22 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022162201A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
US20240076373A1
(en)
|
2021-01-28 |
2024-03-07 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
WO2022165266A1
(en)
|
2021-01-28 |
2022-08-04 |
Compugen Ltd. |
Anti-pvrig antibodies formulations and uses thereof
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
CA3210753A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
US20240117011A1
(en)
|
2021-02-09 |
2024-04-11 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
CA3208365A1
(en)
|
2021-02-15 |
2022-08-18 |
Chantal KUHN |
Cell therapy compositions and methods for modulating tgf-b signaling
|
AR124914A1
(es)
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
AU2022230384A1
(en)
|
2021-03-01 |
2023-09-07 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
EP4301418A1
(en)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
WO2022187863A1
(en)
|
2021-03-05 |
2022-09-09 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
AR126323A1
(es)
|
2021-03-05 |
2023-10-04 |
Iovance Biotherapeutics Inc |
Composiciones para el almacenamiento de tumores y cultivos celulares
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
WO2022192898A2
(en)
|
2021-03-10 |
2022-09-15 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
AU2022238526A1
(en)
|
2021-03-15 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
KR20230158526A
(ko)
|
2021-03-18 |
2023-11-20 |
메디뮨 리미티드 |
Ccr9에 결합하는 치료용 결합 분자
|
EP4308691A1
(en)
|
2021-03-19 |
2024-01-24 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
JP2024511414A
(ja)
|
2021-03-23 |
2024-03-13 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球のcish遺伝子編集及び免疫療法におけるその使用
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
TW202305360A
(zh)
|
2021-03-25 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
用於t細胞共培養效力測定及配合細胞療法產品使用的方法及組合物
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
IL305847A
(en)
|
2021-03-26 |
2023-11-01 |
Innate Pharma |
Multispecific proteins that contain a binding site for NKP46, a binding site for a cancer antigen that is fused to a cytokine to attract NK cells
|
WO2022210485A1
(ja)
|
2021-03-29 |
2022-10-06 |
第一三共株式会社 |
安定な多重特異性分子及びその利用
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
JP2024514281A
(ja)
|
2021-04-23 |
2024-04-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Nk細胞係合剤関連の有害作用の防止または軽減
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
BR112023023777A2
(pt)
|
2021-05-14 |
2024-01-30 |
Genentech Inc |
Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022248870A1
(en)
|
2021-05-28 |
2022-12-01 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
CN117480184A
(zh)
|
2021-06-04 |
2024-01-30 |
中外制药株式会社 |
抗ddr2抗体及其用途
|
AR126089A1
(es)
|
2021-06-07 |
2023-09-13 |
Amgen Inc |
Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
|
BR112023025738A2
(pt)
|
2021-06-09 |
2024-02-27 |
Hoffmann La Roche |
Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
|
CA3218793A1
(en)
|
2021-06-09 |
2022-12-15 |
Laurent Gauthier |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
EP4351733A1
(en)
|
2021-06-09 |
2024-04-17 |
Innate Pharma |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
IL308134A
(en)
|
2021-06-22 |
2023-12-01 |
Novartis Ag |
BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
|
KR20240024074A
(ko)
|
2021-06-23 |
2024-02-23 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
EP4360649A1
(en)
|
2021-06-23 |
2024-05-01 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
MX2023014453A
(es)
|
2021-06-25 |
2024-01-31 |
Chugai Pharmaceutical Co Ltd |
Uso de anticuerpos anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
|
KR102690141B1
(ko)
|
2021-06-25 |
2024-07-30 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法
|
WO2023275621A1
(en)
|
2021-07-01 |
2023-01-05 |
Compugen Ltd. |
Anti-tigit and anti-pvrig in monotherapy and combination treatments
|
WO2023283611A1
(en)
|
2021-07-08 |
2023-01-12 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
AU2022309554A1
(en)
|
2021-07-14 |
2024-02-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
JP2024525769A
(ja)
|
2021-07-14 |
2024-07-12 |
舒泰神(北京)生物製薬股フン有限公司 |
Cd40を特異的に認識する抗体およびその使用
|
AU2022311906A1
(en)
|
2021-07-14 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
EP4373576A1
(en)
|
2021-07-22 |
2024-05-29 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023008459A1
(ja)
|
2021-07-27 |
2023-02-02 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
JPWO2023008461A1
(US20050276830A1-20051215-C00018.png)
|
2021-07-27 |
2023-02-02 |
|
|
AU2022320304A1
(en)
|
2021-07-27 |
2024-02-29 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
CA3227515A1
(en)
|
2021-08-03 |
2023-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions and stable isotope labeling peptide mapping method
|
EP4380978A1
(en)
|
2021-08-07 |
2024-06-12 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
AU2022327742A1
(en)
|
2021-08-13 |
2024-03-14 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
WO2023017484A1
(en)
|
2021-08-13 |
2023-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
KR20240049285A
(ko)
|
2021-08-26 |
2024-04-16 |
쿄와 기린 가부시키가이샤 |
Cd116 및 cd131에 결합하는 이중 특이적 항체
|
WO2023028591A1
(en)
|
2021-08-27 |
2023-03-02 |
Genentech, Inc. |
Methods of treating tau pathologies
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
CN118119409A
(zh)
|
2021-09-03 |
2024-05-31 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
US20230109496A1
(en)
|
2021-09-06 |
2023-04-06 |
Genmab B.V. |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
TW202328439A
(zh)
|
2021-09-09 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
使用pd-1 talen基因減弱生成til產物之方法
|
CN118317795A
(zh)
|
2021-09-15 |
2024-07-09 |
第一三共株式会社 |
用在治疗化疗耐药性癌症的方法中的抗体-药物偶联物
|
EP4401842A1
(en)
|
2021-09-16 |
2024-07-24 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
CA3232223A1
(en)
|
2021-09-17 |
2023-03-23 |
Ying Fu |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
CN115894689A
(zh)
|
2021-09-30 |
2023-04-04 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
TW202332694A
(zh)
|
2021-10-07 |
2023-08-16 |
英商阿凡克塔生命科學公司 |
血清半衰期延長之pd-l1結合多肽
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
TW202330041A
(zh)
|
2021-10-18 |
2023-08-01 |
日商第一三共股份有限公司 |
抗cd37抗體-藥物結合物
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
KR20240099315A
(ko)
|
2021-11-05 |
2024-06-28 |
아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스) |
암배아성 항원에 대한 단클론성 항체 및 이의 용도
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
KR20240100369A
(ko)
|
2021-11-16 |
2024-07-01 |
에이씨 이뮨 에스에이 |
치료 및 진단을 위한 신규한 분자
|
IL312875A
(en)
|
2021-11-18 |
2024-07-01 |
Astrazeneca Uk Ltd |
A combination of an antibody-drug conjugate and a selective PARP1 inhibitor
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
TW202330617A
(zh)
|
2021-11-25 |
2023-08-01 |
大陸商正大天晴藥業集團股份有限公司 |
抗Siglec-15抗體及其應用
|
JPWO2023100829A1
(US20050276830A1-20051215-C00018.png)
|
2021-11-30 |
2023-06-08 |
|
|
CN116829179A
(zh)
|
2021-12-06 |
2023-09-29 |
北京三诺佳邑生物技术有限责任公司 |
特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
AU2022411573A1
(en)
|
2021-12-17 |
2024-06-27 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies and methods of use
|
AU2022408865A1
(en)
|
2021-12-17 |
2024-07-04 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
WO2023126822A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
TW202339805A
(zh)
|
2021-12-28 |
2023-10-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及atr抑制劑之組合
|
AU2023206045A1
(en)
|
2022-01-07 |
2024-08-22 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023139292A1
(en)
|
2022-01-24 |
2023-07-27 |
Cambridge Enterprise Limited |
Tau therapy
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023153471A1
(ja)
|
2022-02-09 |
2023-08-17 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
Fcrl1に結合する抗体又は該抗体断片
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
TW202342520A
(zh)
|
2022-02-18 |
2023-11-01 |
美商樂天醫藥生技股份有限公司 |
抗計畫性死亡配體1(pd—l1)抗體分子、編碼多核苷酸及使用方法
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Rq生物科技有限公司 |
抗體
|
WO2023161875A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
|
WO2023161878A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for folate receptor-expressing cells
|
WO2023161877A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for integrin avb6-expressing cells
|
WO2023161874A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
|
WO2023161876A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for cxcr3-expressing cells
|
WO2023161879A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
|
WO2023161881A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
AU2023236289A1
(en)
|
2022-03-15 |
2024-08-15 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
US20240103010A1
(en)
|
2022-03-18 |
2024-03-28 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
AU2023238766A1
(en)
|
2022-03-23 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
TW202405009A
(zh)
|
2022-03-30 |
2024-02-01 |
瑞士商諾華公司 |
使用抗利尿鈉肽受體1(npr1)抗體治療障礙之方法
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
AR129182A1
(es)
|
2022-04-29 |
2024-07-24 |
23Andme Inc |
Proteínas de unión al antígeno
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202400650A
(zh)
|
2022-05-11 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體與cd47抑制劑之組合
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237706A2
(en)
|
2022-06-08 |
2023-12-14 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
TW202417042A
(zh)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
TW202417504A
(zh)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
抗steap1抗原結合分子及其用途
|
US20240228664A9
(en)
|
2022-07-22 |
2024-07-11 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024026496A1
(en)
|
2022-07-28 |
2024-02-01 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024031032A1
(en)
|
2022-08-05 |
2024-02-08 |
Bristol-Myers Squibb Company |
Anti-ctla-4 antibodies for treatment of kras mutant cancers
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
TW202417034A
(zh)
|
2022-08-19 |
2024-05-01 |
大陸商億一生物醫藥開發(上海)有限公司 |
包含g—csf之調配物及其用途
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024044675A1
(en)
|
2022-08-25 |
2024-02-29 |
Beigene, Ltd. |
Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024097741A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100200A1
(en)
|
2022-11-09 |
2024-05-16 |
Cis Pharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
US20240226313A1
(en)
|
2022-11-17 |
2024-07-11 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
WO2024116094A1
(en)
|
2022-11-30 |
2024-06-06 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugates and dnmt inhibitors
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
WO2024153168A2
(en)
|
2023-01-19 |
2024-07-25 |
Beigene, Ltd. |
Anti-cmet antibodies and methods of use
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|